[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 877
1. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol; 2008 Aug;110(2):196-201
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
  • OBJECTIVE: Tumor markers with increased sensitivity and specificity for endometrial cancer are needed to help monitor response to therapy and to detect recurrent disease.
  • The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus.
  • METHODS: Pre-operative serum samples from surgically staged patients with endometrioid adenocarcinoma of the uterus were analyzed for levels of HE4, SMRP, CA72-4 and CA125.
  • RESULTS: Serum samples from 156 healthy subjects and 171 patients with endometrial cancer (122 stage I, 17 stage II, 26 stage III, and 6 stage IV) were analyzed.
  • At a 95% specificity, the sensitivities for differentiating between healthy subjects and all stages of cancer were 45.5% for HE4 and 24.6% for CA125.
  • CONCLUSION: HE4 is elevated in all stages of endometrial can100cer and is more sensitive in early-stage endometrial cancer compared to CA125.
  • Further investigation of HE4 as a marker for early detection of recurrent endometrial cancer and monitoring response to therapy is warranted.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Endometrial Neoplasms / blood. Epididymal Secretory Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Tumor-Associated, Carbohydrate / blood. CA-125 Antigen / blood. Female. GPI-Linked Proteins. Humans. Membrane Glycoproteins / blood. Middle Aged. Neoplasm Staging. Sensitivity and Specificity. beta-Defensins

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):28-33 [12079296.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):201-9 [12713981.001]
  • [Cites] Am J Obstet Gynecol. 2003 May;188(5):1195-7 [12748476.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):636-43 [15253447.001]
  • [Cites] Am J Obstet Gynecol. 1984 Apr 15;148(8):1057-8 [6201072.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Biometrics. 1988 Sep;44(3):837-45 [3203132.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):292-7 [8088605.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):321-6 [8088608.001]
  • [Cites] Am J Obstet Gynecol. 1996 Apr;174(4):1316-9 [8623863.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):141-6 [8995563.001]
  • [Cites] J Clin Pathol. 1996 Dec;49(12):967-70 [9038731.001]
  • [Cites] Gynecol Oncol. 1997 May;65(2):291-6 [9159340.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):441-7 [9277659.001]
  • [Cites] Cancer Detect Prev. 1999;23(5):397-400 [10468891.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(4):315-7 [10475131.001]
  • [Cites] J Reprod Med. 2005 Aug;50(8):585-90 [16220763.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jul-Aug;12(4):372-5 [12144685.001]
  • (PMID = 18495222.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-72-4 antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / beta-Defensins; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS243878; NLM/ PMC3594093
  •  go-up   go-down


2. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • We report on a very rare case of peritoneal clear cell adenocarcinomas.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • Two peritoneal cystic tumors were detected by imaging modalities around the stomach and spleen, 15 months and 21 months after the follow-up period of the endometrial carcinoma, respectively.
  • They showed proliferation of carcinoma cells arranged in solid nest, tubular, and papillary patterns.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • The morphologies and immunohistochemical findings of the two peritoneal clear cell adenocarcinomas were different from those of endometrial carcinoma.
  • We believe that the two clear cell adenocarcinomas are not metastatic lesions from the endometrial carcinoma of the uterus, and that they are primary clear cell adenocarcinomas of the peritoneum.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Castilho MS, Jacinto AA, Viani GA, Campana A, Carvalho J, Ferrigno R, Novaes PE, Fogaroli RC, Salvajoli JV: Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney. Radiat Oncol; 2006;1:44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney.
  • BACKGROUND: Pelvic Radiotherapy (RT) as a postoperative treatment for endometrial cancer improves local regional control.
  • CASE: We report on a 50 year-old patient with a serous-papiliferous adenocarcinoma of the uterus who was submitted to surgical treatment without lymph node sampling followed by Brachytherapy, and Chemotherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Radiotherapy, Intensity-Modulated / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2000 Sep 15;70(5):844-6 [11003368.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1004-9 [14575831.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):376-9 [14751190.001]
  • [Cites] J Urol. 1980 May;123(5):766-7 [7420573.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):977-83 [1976615.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Aug;42(2):174-6 [7901069.001]
  • [Cites] Transplantation. 1994 Aug 27;58(4):520-2 [8073523.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):151-5 [7557603.001]
  • [Cites] J Surg Oncol. 1996 Sep;63(1):57-60 [8841468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):834-8 [15927414.001]
  • [Cites] Radiother Oncol. 2005 Oct;77(1):11-7 [16024116.001]
  • (PMID = 17116263.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1660561
  • [General-notes] NLM/ Original DateCompleted: 20070809
  •  go-up   go-down


Advertisement
4. Gates EJ, Hirschfield L, Matthews RP, Yap OW: Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium. J Natl Med Assoc; 2006 Nov;98(11):1814-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium.
  • OBJECTIVE: To determine if body mass index (BMI) influences tumor expression of HER-2/neu, estrogen and progesterone receptors (ER/PR), and survival in women with endometrial adenocarcinoma.
  • METHODS: Patients diagnosed between January 1992 and December 2001 with endometrioid adenocarcinoma of the uterus were identified.
  • CONCLUSION: In patients with endometrioid adenocarcinoma, low BMI is associated with high stage and tumor expression of HER-2/neu.
  • [MeSH-major] Body Mass Index. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / physiopathology. Endometrial Neoplasms / mortality. Endometrial Neoplasms / physiopathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1979 Sep;54(3):269-77 [471366.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1055-60 [333120.001]
  • [Cites] Cancer Res. 1981 Mar;41(3):1140-7 [6936073.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):388-93 [11606102.001]
  • [Cites] JAMA. 1980 Nov 28;244(21):2419-22 [7431569.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):360-8 [16633364.001]
  • [Cites] Int J Epidemiol. 2006 Feb;35(1):151-8 [16278243.001]
  • [Cites] Am J Epidemiol. 2005 May 15;161(10):939-47 [15870158.001]
  • [Cites] Cancer. 1949 Nov;2(6):964-71, illust [15395195.001]
  • [Cites] Int J Gynecol Pathol. 1999 Apr;18(2):138-43 [10202671.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):25-9 [9577367.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5077-85 [9371506.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):138-42 [9103403.001]
  • [Cites] Cancer Lett. 1996 Jan 2;98(2):151-5 [8556702.001]
  • [Cites] Am J Obstet Gynecol. 1995 Dec;173(6):1829-34 [8610771.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5693-8 [7585656.001]
  • [Cites] Nutr Cancer. 1995;23(2):141-9 [7644383.001]
  • [Cites] Am J Obstet Gynecol. 1994 Nov;171(5):1193-8 [7977518.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1604-7 [8137266.001]
  • [Cites] Gynecol Oncol. 1993 Feb;48(2):196-202 [8428691.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2157-62 [7127255.001]
  • [Cites] Pathol Res Pract. 1982 Aug;174(3):237-56 [7145769.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Obstet Gynecol. 1984 Jul;64(1):1-11 [6738931.001]
  • [Cites] Cancer Treat Rep. 1985 Feb;69(2):237-8 [3971394.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1452-5 [4027879.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Am J Obstet Gynecol. 1988 Apr;158(4):796-807 [2966586.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):364-6 [2227549.001]
  • [Cites] Rev Fr Gynecol Obstet. 1990 Oct;85(10):513-6 [2263829.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):15-21 [1670908.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):179-85 [1361478.001]
  • (PMID = 17128692.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2569783
  •  go-up   go-down


5. Vasil'eva EV, Belianin VL: [Serous adenocarcinoma of the uterus: criteria of morphological diagnosis and immunohistochemistry]. Arkh Patol; 2005 Mar-Apr;67(2):25-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serous adenocarcinoma of the uterus: criteria of morphological diagnosis and immunohistochemistry].
  • The analysis of the histopathologic features in 138 patients with uterine serous adenocarcinoma in comparison with 146 patients with uterine endometrioid papillary adenocarcinoma revealed morphological specificities of these carcinomas.
  • Immunohistochemical study found that 66.7% uterine serous adenocarcinomas were negative both to estrogen and progesterone receptors and 86.7% uterine serous adenocarcinomas showed p53 oncoprotein overexpression.
  • The data support the hypothesis that uterine serous adenocarcinoma is a hormone-negative tumor and that mutation of p53 tumor suppressor gene may play a leading role in its carcinogenesis.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Endometrial Neoplasms / diagnosis. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938115.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


6. Krepinska E, Kriz JT, Laco J: Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman. Eur J Gynaecol Oncol; 2010;31(5):584-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
  • Synchronous primary cancers of the endometrium and ovary occur in approximately 10% of all women with ovarian cancer and 5% of all women with endometrial cancer.
  • The pathogenesis of synchronous endometrial and ovarian cancer is unclear.
  • We report a case of unusual co-existence of endometroid adenocarcinoma of the uterus, serous borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061809.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Montalto SA, Hakmi A, Moth P, Raju KS, Coutts M, Papadopoulos AJ, Devaja O: Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case? Eur J Gynaecol Oncol; 2009;30(1):35-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case?
  • OBJECTIVE: The purpose of this study was to investigate what proportion of cases showing a well differentiated endometrioid endometrial adenocarcinoma in the hysterectomy specimen removed at two UK cancer centres had adverse pathological features or advanced stage disease at the time of presentation.
  • STUDY DESIGN: Ninety-eight patients who were operated on at either the South East London Cancer Centre, London or the Kent Oncology Centre, Maidstone had a histological diagnosis of well differentiated (grade 1) endometrioid adenocarcinoma in their hysterectomy specimen.
  • RESULTS: Of the initial 98 cases, 65 patients (66.3%) were referred with a preoperative curettage showing a well differentiated endometrioid adenocarcinoma, 25 cases (25.5%) were referred with atypical endometrial hyperplasia, seven patients (7.1%) were referred with a moderately differentiated endometrioid adenocarcinoma, and one case (1.0%) was referred with a possible malignant mixed Mullerian tumour.
  • Subsequent histological examination of the hysterectomy specimens revealed that all of these cases had a well differentiated endometrioid adenocarcinoma.
  • From our study, 33.6% of cases with a well differentiated endometrioid adenocarcinoma of the uterus were Stage Ic or more at the time of presentation; 12.2% were at least FIGO Stage Ic, eight patients (8.2%) were FIGO Stage IIa, seven patients (7.1%) were Stage IIb and six patients (6.1%) were Stage III.
  • Cases with a preoperative biopsy showing atypical hyperplasia or well differentiated adenocarcinoma should have a preoperative MRI scan or preferably an intraoperative frozen section examination to identify those cases with adverse pathological features which need to be fully staged with pelvic and paraaortic lymphadenectomy.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317254.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


8. Kurotaki T, Kokoshima H, Kitamori F, Kitamori T, Tsuchitani M: A case of adenocarcinoma of the endometrium extending into the leiomyoma of the uterus in a rabbit. J Vet Med Sci; 2007 Sep;69(9):981-4
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of adenocarcinoma of the endometrium extending into the leiomyoma of the uterus in a rabbit.
  • In a pet rabbit, 2 tumor masses one on each horn were macroscopically seen in the wall of the uterus.
  • The tumor was diagnosed as an adenocarcinoma of the endometrium.
  • While adenocarcinoma cells formed a protrusive mass in the uterine lumen, they also showed an extension into the leiomyoma of the myometrium.
  • By immunohistochemistry, adenocarcinoma stained positive for cytokeratin (MNF116) and leiomyoma stained positive for smooth muscle actin, showing a substantial difference in the cytological nature of these tumor cells.
  • The results may give a further evidence supporting the narrative of the tumor development that an adenocarcinoma of the endometrium extended into leiomyoma of the uterus.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917388.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Kumar VJ, Nin CY, Kuei LY, Tan KH, Yeo R, Lam PY: Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy. Int J Gynecol Cancer; 2010 May;20(4):564-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy.
  • INTRODUCTION: Advanced age, deep myoinvasion, whole cavity or lower uterine segment tumors, poor differentiation, and lymphovascular space invasion are known to increase recurrence risk and adversely affect survival in stage I endometrioid adenocarcinoma of the uterus.
  • METHODS: Data of 162 patients with surgical stage I endometrioid adenocarcinoma of the uterus with an increased risk of recurrence were reviewed from the year 1997 to 2008 at KK Gynaecological Cancer Centre, Singapore.
  • Most patients (54.3%) had surgical stage IC endometrioid adenocarcinoma, whereas the rest had stage IB.
  • Age, lymphovascular space invasion, and tumor volume and location were not significant parameters in surgical stage I endometrioid adenocarcinoma patients who failed.
  • The median survival for recurrent endometrial cancer was 5 years.
  • [MeSH-major] Brachytherapy. Carcinoma, Endometrioid / mortality. Endometrial Neoplasms / mortality. Neoplasm Recurrence, Local / mortality. Radiotherapy, Adjuvant / mortality. Uterine Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686374.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Nabli H, Tuller E, Sharpe-Timms KL: Haptoglobin expression in endometrioid adenocarcinoma of the uterus. Reprod Sci; 2010 Jan;17(1):47-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haptoglobin expression in endometrioid adenocarcinoma of the uterus.
  • OBJECTIVE: Elevated serum haptoglobin (Hp) concentrations have been reported in patients with malignant diseases.
  • We have shown that Hp is produced by and localizes only in the stroma and not the epithelium of endometriotic lesions, which share many characteristics of carcinoma.
  • Furthermore, Hp mRNA and protein are found exclusively in the stroma of eutopic endometrium from women with endometriosis and not those without endometriosis.
  • We hypothesized that characteristic patterns of Hp gene expression and protein localization in endometrioid adenocarcinoma of the uterus may provide insight into the clinical utility of Hp as a tumor marker or alternative therapeutic approach.
  • METHODS: Biopsies of endometrioid adenocarcinoma tumors of the uterus and their adjacent nonaffected endometrium were collected.
  • Normal endometrium was collected from healthy women.
  • RESULTS: Haptoglobin mRNA levels were significantly greater (P < .005) in endometrioid adenocarcinoma and adjacent nonaffected endometrial tissues than normal endometrium.
  • No correlation was found between Hp levels and cancer stage (P = .673) or grade (P = .739).
  • Haptoglobin protein localized in both stromal and glandular epithelial cells of endometrioid adenocarcinoma and their adjacent nonaffected tissue but not in control endometrium.
  • CONCLUSIONS: Our results have identified, for the first time, unique patterns of Hp mRNA expression and protein localization in the stromal and glandular epithelial cells of endometrioid adenocarcinoma of the uterus.
  • We propose that this unique pattern of endometrioid adenocarcinoma Hp expression may be developed as a novel diagnostic marker.
  • Modulation of Hp, with its immunomodulatory and angiogenic properties, may generate novel methods of prevention or treatment for endometrial cancer.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Haptoglobins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801537.001).
  • [ISSN] 1933-7205
  • [Journal-full-title] Reproductive sciences (Thousand Oaks, Calif.)
  • [ISO-abbreviation] Reprod Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Haptoglobins; 0 / RNA, Messenger
  •  go-up   go-down


11. Bigsby GE 4th, Holloway RW, Weppelman B, Reynolds RB, Williams B: Endometroid adenocarcinoma of the uterus with cardiac metastasis. A case report and six-year follow-up. Gynecol Oncol; 2005 Apr;97(1):256-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometroid adenocarcinoma of the uterus with cardiac metastasis. A case report and six-year follow-up.
  • BACKGROUND: There are few reported cases of cardiac metastasis associated with endometrial cancer (EC) and no reports of long-term survival.
  • A total abdominal hysterectomy with pelvic and para-aortic lymhadenectomy was performed with disease confined to the uterus/cervix.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Heart Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790471.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Pozharisskiĭ KM, Samsonova EA, Ten VP, Maksimova NA, Urmancheeva AF: [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value]. Arkh Patol; 2005 Mar-Apr;67(2):13-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value].
  • 76 endometrioid adenocarcinomas of the uterine body were studied.
  • Expression of the above markers is of essential value together with metastatic involvement of regional lymph nodes, stage of the disease and pathogenetic variant for determining prognosis of carcinoma aggressiveness and disease outcome.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ki-67 Antigen / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Steroid / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938112.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Steroid; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


13. Marquette A, Moerman P, Vergote I, Amant F: Second case of uterine mesonephric adenocarcinoma. Int J Gynecol Cancer; 2006 May-Jun;16(3):1450-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second case of uterine mesonephric adenocarcinoma.
  • A second report of an intramural mesonephric adenocarcinoma of the uterus is presented.
  • The histogenesis and clinicopathologic outcome of a surgically staged malignancy add to the insights and experience of this uncommon disorder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Mesonephroma / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / metabolism. Calbindin 2. Female. Humans. Immunohistochemistry / methods. Neoplasm Invasiveness / diagnosis. S100 Calcium Binding Protein G / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803547.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G
  • [Number-of-references] 18
  •  go-up   go-down


14. Akcaer M, Milman T, Finger PT: Imaging of endometrioid adenocarcinoma of the uterus metastatic to the ciliary body. Ophthalmic Surg Lasers Imaging; 2008 May-Jun;39(3):246-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of endometrioid adenocarcinoma of the uterus metastatic to the ciliary body.
  • A 60-year-old woman with endometrioid adenocarcinoma (stage FIGO II) presented with left eye pain.
  • A Finger iridectomy technique ciliary body tumor biopsy revealed metastatic endometrioid adenocarcinoma.
  • This is the first reported case of endometrioid adenocarcinoma of the uterus metastatic to the uveal tract.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / secondary. Ciliary Body. Endometrial Neoplasms / pathology. Uveal Neoplasms / diagnosis. Uveal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556953.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Bermudez Wagner KM, Thomas MB, Miyamoto C, Micaily B, Hernandez E: Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA). J Clin Oncol; 2009 May 20;27(15_suppl):e16511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA).
  • : e16511 Background: Pelvic lymph node dissection (LND) requirement to adequately stage endometrial cancer has been subject of debate.
  • We conducted an outcome analysis of clinical stage I endometrioid endometrial adenocarcinoma (EEA) patients who underwent surgery with tailored LND and adjuvant therapy (radiation (RT) or chemotherapy) between 1997 and 2008.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Arnaoutakis K, Morse AB, Ambika S, Wong G, Parameswaran R: Practice-based improvement (PBI) via web based tool (WBT) in multidisciplinary gynecologic oncology clinic (MGOC). J Clin Oncol; 2009 May 20;27(15_suppl):e17545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Few studies document evaluation of risk of late side effects of cancer therapy.
  • Part 1 evaluation showed that 68 % pts had endometrial adenocarcinoma; 20% cervical cancer; 12% uterine sarcoma or carcinosarcoma.
  • No pts had complete fall risk evaluation, estimated dietary calcium (Ca)/vitamin D intake or documented adequacy of Ca or vit D intake.
  • Counseling for appropriate Ca/vitamin D intake was poor (4%/8%).
  • We have targeted areas for improvement for part 2: vit D level evaluation, assessment of and counseling for adequate of Ca/ vit D intake and WBE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963762.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Qian J, Weber D, Cochran R, Hossain D, Bostwick DG: Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH). J Clin Oncol; 2009 May 20;27(15_suppl):5533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH).
  • : 5533 Background: Endometrial cancer is the most common pelvic gynecological malignancy.
  • The diagnosis of well-differentiated endometrial adenocarcinoma, atypical hyperplasia, and marked hyperplasia is often challenging.
  • We sought to investigate the utility of chromosomal anomalies for the detection of uterine endometrial carcinoma using multitarget fluorescence in situ hybridization (FISH).
  • METHODS: Samples were collected by endometrial brush and processed by liquid-based thin-layer cytological preparation protocol.
  • For study, we collected cytology slides from consecutive cases to include 50 benign, 50 hyperplasia without atypia, 50 atypical hyperplasia, and 50 endometrial cancers.
  • The FISH signals were enumerated in 100 cells per case, and the chromosomal anomalies were correlated with pathologic findings, including histologic diagnoses on endometrial tissue samples.
  • RESULTS: Numeric chromosomal anomalies were found in 0% (0/50) of benign, 20% (10/50) of hyperplasia, 76% of atypical hyperplasia (38/50), and 86% (43/50) of carcinoma specimens.
  • The mean percentage of cells with chromosomal changes was 54% in cancer specimens, significantly higher than that in hyperplasia without atypia (13%, p< 0.0001) and atypical hyperplasia (34%, p< 0.0001).
  • FISH anomalies had an overall sensitivity of 81% and specificity of 90% for the detection of atypical hyperplasia and/or endometrial carcinoma.
  • There was no association with grade of endometrial carcinoma.
  • CONCLUSIONS: Multi-target UteroFISH appeared to be useful for the differential diagnosis of reactive hyperplasia, atypical hyperplasia, and endometrial adenocarcinoma, with a high level of sensitivity and specificity.
  • Endometrial hyperplasia with FISH-detected chromosomal anomalies may require close clinical follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962491.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Espino-Strebel E, Luna JT: Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer.
  • : e16524 Background: Poor prognostic factors dictating the need for extended surgical staging among endometrial cancer patients can be accurately determined only after laparotomy.
  • This prospective study was conducted to determine the correlation between preoperative serum CA125 and surgicopathologic prognostic factors in endometrial cancer.
  • METHODS: Endometrial cancer patients diagnosed from October 2006 to July 2008 who were eligible for primary surgical treatment were included.
  • RESULTS: Ninety patients with endometrioid endometrial adenocarcinoma were included.
  • It is recommended that serum CA125 determination be part of the preoperative work-up of endometrial cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960797.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ackerman I: Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument. Int J Gynecol Cancer; 2010 Oct;20(11 Suppl 2):S67-9
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument.
  • Adjuvant external beam pelvic radiation therapy for stage I endometrial cancer has become increasingly confusing and controversial.
  • By using evidence from the literature, including the most recent randomized data, an argument is made for the use of external beam pelvic radiotherapy for a 63-year-old woman who has undergone a total abdominal hysterectomy and bilateral salpingo-oophorectomy for a grade 2 endometrioid adenocarcinoma of the uterus with 9 of 12 mm of invasion and the presence of lymphovascular space involvement.
  • [MeSH-major] Carcinoma, Endometrioid / prevention & control. Carcinoma, Endometrioid / radiotherapy. Endometrial Neoplasms / prevention & control. Endometrial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053530.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


20. Kato K, Suzuka K, Osaki T, Itami M, Tanaka N: Primary hepatoid adenocarcinoma of the uterine cervix. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):1150-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatoid adenocarcinoma of the uterine cervix.
  • Hepatoid adenocarcinoma is characterized histologically by neoplastic epithelial cells that resemble hepatocellular carcinoma (HCC) and produce alpha-fetoprotein (AFP).
  • We describe a case of hepatoid adenocarcinoma of the uterus that, unlike any other previously reported case, was strictly confined to the cervix.
  • A cervical biopsy demonstrated poorly differentiated adenocarcinoma, and hysterectomy and bilateral salpingo-oophorectomy were subsequently performed.
  • Histologically, the lesion consisted of solid sheets of hepatoid cells accompanied with areas of endometroid adenocarcinoma.
  • The tumor cells showed strong and diffuse cytoplasmic immunoreactivity with AFP in both medullary and adenocarcinoma components.
  • To our knowledge, this is the first report of primary hepatoid adenocarcinoma of the uterine cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367323.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 15
  •  go-up   go-down


21. Pozharisskiĭ KM, Vinokurov VL, Zharinov GM, Bolbarian NA, Kuznetsova ME, Gasparian NA, Samsonova EA: [Immunohistochemical markers as prognosticators in gynecologic oncology]. Vopr Onkol; 2008;54(4):463-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclooxygenase and particularly COX-2 expression impaired survival in patients operated on for endometrial adenocarcinoma of the uterus: 5-year overall and relapse-free survival in absence of expression was 92% and 88%, respectively, while in cases of distinct expression, it fell down to 52% and 48%, respectively (p = 0.0004; 0.0005).
  • The end-results of radiotherapy were associated with proliferative levels of squamous cell cervical carcinoma: for Ki-67--below median of < or = 50%, 5-year survival rate was 77%, mean survival--80 months; for Ki-67 above median of > or = 50%, the indices were 47% and 47 months, respectively, (p = 0.002).
  • [MeSH-major] Biomarkers, Tumor / analysis. Genital Neoplasms, Female / chemistry. Genital Neoplasms, Female / diagnosis. Immunohistochemistry
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adult. Aged. Cyclooxygenase 1 / analysis. Cyclooxygenase 2 / analysis. Disease-Free Survival. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Female. Gene Expression Regulation, Developmental. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Tumor Suppressor Protein p53 / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942401.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


22. Pfister P, Geissbuehler U, Wiener D, Hirsbrunner G, Kaufmann C: Pollakisuria in a dwarf goat due to pathologic enlargement of the uterus. Vet Q; 2007 Sep;29(3):112-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pollakisuria in a dwarf goat due to pathologic enlargement of the uterus.
  • Hydrometra is the most common cause of uterine distension in goats and usually can be resolved by prostaglandin injections.
  • But other pathologies of the uterus can generate a similar syndrome.
  • A laparotomy was performed and an enlarged uterus with 1.5 L of mucous content and cystic ovaries were found and partially removed.
  • A single solid leiomyoma was diagnosed histologically in the uterine wall.
  • Necropsy and pathohistological examination revealed the presence of a metastasized adenocarcinoma of the uterus.
  • In this case, the pollakisuria provoqued by distension of the uterus was not caused by hydrometra, but by neoplasia.
  • The syndrome and the pathogenesis of the adenocarcinoma in consideration of the hormonal status of the patient is discussed.
  • [MeSH-major] Adenocarcinoma / veterinary. Goat Diseases / diagnosis. Leiomyoma / veterinary. Polyuria / veterinary. Uterine Neoplasms / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Female. Goats

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970288.001).
  • [ISSN] 0165-2176
  • [Journal-full-title] The Veterinary quarterly
  • [ISO-abbreviation] Vet Q
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Cutillo G, Cignini P, Visca P, Vizza E, Sbiroli C: Endometrial biopsy by means of the hysteroscopic resectoscope for the evaluation of tumor differentiation in endometrial cancer: a pilot study. Eur J Surg Oncol; 2007 Sep;33(7):907-10
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial biopsy by means of the hysteroscopic resectoscope for the evaluation of tumor differentiation in endometrial cancer: a pilot study.
  • AIMS: To assess the diagnostic accuracy of endometrial biopsy by means of the hysteroscopic resectoscope (EBHR) in evaluating tumor differentiation in patients with endometrial cancer.
  • METHODS: Between January and December 2005, all the women with a diagnosis of endometrioid adenocarcinoma of the uterus, when admitted to hospital, were enrolled for this study.
  • CONCLUSION: EBHR is a very accurate diagnostic procedure for assessing the preoperative tumor grade in patients with endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrium / pathology. Hysteroscopes. Hysteroscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Surg Oncol. 2007 Oct;33(8):1047-8 [17336480.001]
  • (PMID = 17188830.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Klopp AH, Jhingran A, Ramondetta L, Lu K, Gershenson DM, Eifel PJ: Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol; 2009 Oct;115(1):6-11
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
  • OBJECTIVE: To evaluate treatment outcomes and patterns of recurrence in patients with node-positive (International Federation of Obstetrics and Gynecology stage IIIC) adenocarcinoma of the uterus without serous or clear cell differentiation.
  • METHODS: The records of 71 women who were treated for stage IIIC endometrial adenocarcinoma at our institution between 1984 and 2005 were reviewed.
  • Patients with stage IIIC endometrial adenocarcinoma who underwent surgical staging followed by external beam irradiation had a high rate of cure.
  • Relapses in patients treated with EBRT primarily occurred in patients with grade 3 cancer who may be most likely to benefit from combined-chemoradiation treatment.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632709.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, Wright JD: Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstet Gynecol; 2010 Nov;116(5):1141-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer.
  • METHODS: Women with endometrioid adenocarcinoma of the uterus treated between 1988 and 2006 and recorded in the Surveillance, Epidemiology, and End Results database were analyzed.
  • CONCLUSION: The 2009 FIGO staging system for uterine corpus cancer is highly prognostic.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Obstet Gynecol. 2011 May;117(5):1225-6; author reply 1226 [21508766.001]
  • (PMID = 20966700.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Stone P, Burnett A, Burton B, Roman J: Overcoming extreme obesity with robotic surgery. Int J Med Robot; 2010 Dec;6(4):382-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Obesity is often associated with endometrial cancer and has posed a challenge in surgical management.
  • For the patient with uterine cancer, surgery is necessary for staging, control of symptoms and cure.
  • While surgery is the principal modality for the treatment and management of uterine cancer, the morbidly obese patient faces increased complications and longer postoperative recovery.
  • She was diagnosed with endometrioid adenocarcinoma of the uterus, FIGO grade 1.
  • CONCLUSIONS: Since obesity is a significant risk factor for endometrial cancer and the prevalence of obesity is increasing, developing surgical techniques to appropriately manage these patients is important.
  • With the increasing obesity of our population and the high prevalence of uterine cancer, further advancement of equipment, anaesthesia and surgical techniques to accommodate the larger patient while decreasing complications have yet to be standardized.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Laparoscopy / methods. Obesity, Morbid / complications. Robotics / methods

  • Genetic Alliance. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20812220.001).
  • [ISSN] 1478-596X
  • [Journal-full-title] The international journal of medical robotics + computer assisted surgery : MRCAS
  • [ISO-abbreviation] Int J Med Robot
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Oztürk HB, Vural B, Calışkan E, Solakoğlu S: Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines. J Turk Ger Gynecol Assoc; 2010;11(3):131-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines.
  • OBJECTIVE: The aim of this study was to compare apoptotic and antiproliferative effects of gonadotropin-releasing hormone analogues and their combination with octeotide on endometrioid endometrial cancer cell lines.
  • MATERIAL AND METHOD: Women diagnosed with endometrioid adenocarcinoma at the department of Gynecology and Obstetric of Kocaeli University Medical School were included in this research.
  • Endometrium cancer cell lines obtained from three patients were used for this study.
  • CONCLUSION: GnRH analogues appears to have a direct effect, enhancing the apoptotic index and decreasing the cell proliferation in endometrial adenocancer cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24591918.001).
  • [ISSN] 1309-0399
  • [Journal-full-title] Journal of the Turkish German Gynecological Association
  • [ISO-abbreviation] J Turk Ger Gynecol Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC3939219
  • [Keywords] NOTNLM ; Endometrial cancer / apoptosis / cell proliferation / gonadotropin-releasing hormone analogues / octreotide
  •  go-up   go-down


28. Tretheway D, Gebhardt JG, Dogra VS, Schiffhauer LM: Metastatic versus primary oncocytic papillary adenocarcinoma of the endometrium: a report of a case and review of the literature. Int J Gynecol Pathol; 2009 May;28(3):256-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic versus primary oncocytic papillary adenocarcinoma of the endometrium: a report of a case and review of the literature.
  • We report a case of an oncocytic papillary adenocarcinoma of the endometrium in an 89-year-old female with vaginal bleeding.
  • Imaging studies revealed lesions in the uterus, kidneys, pancreas, gluteus, and an enlarged portacaval lymph node.
  • Diagnostic workup included an endometrial biopsy which showed malignant, oncocytic cells in a predominantly papillary pattern.
  • The cells were negative for cytokeratin 903, CAM 5.2, progesterone receptor, CD10, RCC Marker, CA-125, c-kit, and vimentin.
  • Consultation with experts in Gynecologic and Genitourinary pathology returned a diagnosis of "adenocarcinoma compatible with metastatic renal cell carcinoma"--an intriguing possibility worthy of further exploration.
  • To our knowledge, there are no reports in the literature of metastatic oncocytic papillary renal cell carcinoma to the endometrium.
  • The clinical and pathologic features of oncocytic papillary endometrial lesions, including primary and metastatic processes, are reviewed.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620943.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


29. Golbar H, Izawa T, Kuwamura M, Ito S, Yamate J: Uterine adenocarcinoma with prominent desmoplasia in a geriatric miniature pig. J Vet Med Sci; 2010 Feb;72(2):253-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenocarcinoma with prominent desmoplasia in a geriatric miniature pig.
  • Grossly, neoplastic enlargement of the uterus was found.
  • Based on these findings, a diagnosis of uterine adenocarcinoma with marked desmoplasia was made.
  • This case is the second report of uterine adenocarcinoma in the miniature pig.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19942805.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Stilwell G, Peleteiro MC: Uterine adenocarcinoma with pulmonary, liver and mesentery metastasis in a holstein cow. Vet Med Int; 2010;2010:727856

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenocarcinoma with pulmonary, liver and mesentery metastasis in a holstein cow.
  • The clinical and pathology features of a cow with uterine adenocarcinoma and multiple metastasis are described.
  • Grossly deformed uterus, enlarged iliac lymph nodes, and rosary arranged nodules in the mesentery were felt by rectal palpation.
  • Necropsy and histopathology exam revealed a uterine adenocarcinoma with multiple pulmonary, liver and mesentery metastasis.
  • Uterine adenocarcinoma with metastasis should be included in the differential diagnosis of cows showing weight loss and mild respiratory distress and palpation of numerous firm nodules in the mesentery should be suggestive of neoplasias' metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Vet Med Assoc. 1970 Dec 1;157(11):1577-84 [4098649.001]
  • [Cites] J Am Vet Med Assoc. 1966 Apr 15;148(8):913-5 [5950882.001]
  • [Cites] J Comp Pathol. 1969 Jan;79(1):53-63 [5813284.001]
  • (PMID = 20445789.001).
  • [ISSN] 2042-0048
  • [Journal-full-title] Veterinary medicine international
  • [ISO-abbreviation] Vet Med Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2860195
  •  go-up   go-down


31. Wilson M, Hermes R, Bainbridge J, Bassett H: A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum). J Zoo Wildl Med; 2010 Mar;41(1):111-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum).
  • The rhinoceros' uterus had previously been evaluated by ultrasound and diffuse endometrial hyperplasia and two benign uterine leiomyomas had been diagnosed.
  • At necropsy examination, a large, infiltrative, metastatic uterine adenocarcinoma was found multifocally throughout the uterus, scattered within the peritoneal cavity, on the diaphragm, the splenic capsule, the pleural surface of the lung and mesenteric lymph nodes.
  • [MeSH-major] Adenocarcinoma / veterinary. Lung Neoplasms / veterinary. Perissodactyla. Peritoneal Neoplasms / veterinary. Splenic Neoplasms / veterinary. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722262.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Arai T, Watanabe J, Kawaguchi M, Kamata Y, Nishimura Y, Jobo T, Kuramoto H: Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):391-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma.
  • Clear cell adenocarcinoma (CCA) of the endometrium has a poor prognosis, although the biologic features of this rare tumor are not clear.
  • Thirteen cases of CCA were compared with cases of endometrioid adenocarcinoma (EMA) of the endometrium.
  • Immunohistochemical staining for p53; Ki-67; cyclins A, D1, and E; E-cadherin; progesterone receptor (PR)-A and PR-B; P-glycoprotein; MLH1; and MSH2 was performed.
  • No CCAs were positive for PR-A and PR-B.
  • The mechanism of cell-cycle regulation in endometrial CCA is different from that in EMA and may influence its malignant potential.
  • Endometrial CCA is a distinct entity from EMA.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Endometrioid / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Cyclin A / analysis. Cyclin D1 / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity. Tumor Suppressor Protein p53

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445664.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cyclin A; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


33. Preissel AK, Brugger N, Stassen T, Nuss K: [Treatment of a uterine adenocarcinoma in a miniature pig by ovariohysterectomy]. Schweiz Arch Tierheilkd; 2009 May;151(5):229-32
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of a uterine adenocarcinoma in a miniature pig by ovariohysterectomy].
  • A ventral midline approach was chosen to remove the ovaries and uterus, which contained brown fluid and multifocal masses in the uterine wall.
  • Histological examination of the uterine masses revealed leiomyoma, cystic hyperplasia and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / veterinary. Hysterectomy / veterinary. Ovariectomy / veterinary. Swine Diseases / surgery. Swine, Miniature. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19421955.001).
  • [ISSN] 0036-7281
  • [Journal-full-title] Schweizer Archiv für Tierheilkunde
  • [ISO-abbreviation] Schweiz. Arch. Tierheilkd.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


34. Lin CK, Yu MH, Chu TW, Lai HC: Synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium. Taiwan J Obstet Gynecol; 2006 Dec;45(4):336-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium.
  • OBJECTIVE: Synchronous primary malignant neoplasms of the uterus are uncommon.
  • Patients with synchronous cervical and endometrial cancers are even rarer.
  • We describe a case of cervical squamous cell carcinoma and endometrial endometrioid adenocarcinoma occurring simultaneously in a 47-year-old woman presenting with massive menstrual bleeding.
  • Magnetic resonance imaging revealed a mass over the cervical region and endometrial lesions in the uterine cavity.
  • Surgical exploration disclosed a cervical tumor and erosion of the endometrium.
  • The pathologic findings were compatible with synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium.
  • It is practical to pay more attention to the differential diagnosis of primary and metastatic tumors.
  • The second primary cancer that occurs in an individual with endometrial cancer may offer an opportunity for early detection.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endometrial Neoplasms / diagnosis. Female. Humans. Lymphatic Metastasis / diagnosis. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175494.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


35. Shirley S, Devi VS, Krishnamurthy R, Nabhi MV, Majhi U, Selvaluxmy G: Endometrial adenocarcinoma involving both horns of a bicornuate uterus. J Cancer Res Ther; 2010 Jul-Sep;6(3):304-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma involving both horns of a bicornuate uterus.
  • We report a rare case of endometrial adenocarcinoma involving both horns of a bicornuate uterus in a postmenopausal woman.
  • Patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and bilateral pelvic lymph node dissection following an initial positive diagnosis of well differentiated endometrioid adenocarcinoma on endometrial biopsy.
  • Endometrial carcinoma arising in malformed uterus is rare.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Uterus / abnormalities

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119258.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


36. Takeuchi K, Kitazawa S, Hamanishi S, Inagaki M, Murata K: A case of alpha-fetoprotein-producing adenocarcinoma of the endometrium with a hepatoid component as a potential source for alpha-fetoprotein in a postmenopausal woman. Int J Gynecol Cancer; 2006 May-Jun;16(3):1442-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of alpha-fetoprotein-producing adenocarcinoma of the endometrium with a hepatoid component as a potential source for alpha-fetoprotein in a postmenopausal woman.
  • Although case reports of alpha-fetoprotein (AFP)-producing adenocarcinoma other than hepatocellular carcinoma have gradually increased in number, AFP-producing adenocarcinoma of the endometrium is very rare.
  • Radiologic imaging and endoscopy did not provide evidence of any primary carcinoma in the liver and gastrointestinal tract.
  • To investigate the unknown origin of high AFP, Pap smear of the endometrium followed by fractional curettage was performed and revealed adenocarcinoma of the endometrium.
  • Histologic study showed a mixture of major AFP-negative endometrioid adenocarcinoma and minor medullary proliferation of the AFP-positive hepatoid adenocarcinoma cells with eosinophilic cytoplasm and hyaline globules.
  • The possible existence of AFP-producing adenocarcinoma of the endometrium should be considered in a postmenopausal woman even if there is no vaginal bleeding, when AFP-producing tumor is clinically suspected and the imaging studies fail to confirm the diagnosis.
  • [MeSH-major] Carcinoma, Endometrioid / secretion. Carcinoma, Hepatocellular / secondary. Endometrial Neoplasms / secretion. alpha-Fetoproteins / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803544.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 10
  •  go-up   go-down


37. Nishimura Y, Watanabe J, Jobo T, Hattori M, Arai T, Kuramoto H: Cytologic scoring of endometrioid adenocarcinoma of the endometrium. Cancer; 2005 Feb 25;105(1):8-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic scoring of endometrioid adenocarcinoma of the endometrium.
  • BACKGROUND: Endometrial carcinoma is one of the most frequent malignancies in the female genital tract, and its incidence has been increasing in Japan.
  • The objective of this study was to evaluate the applicability and usefulness of cytologic scoring in assessing the morphologic differentiation of endometrioid adenocarcinomas of the endometrium using endometrial smears.
  • METHODS: Sixty-four endometrial cytologic samples of endometrioid adenocarcinomas of the endometrium were used in this study.
  • All patients underwent endometrial cytology before hysterectomy, and the diagnosis was confirmed by histologic examination of the extirpated uterus.
  • The best cut-off value for distinguishing histologic Grade 1 from the others was a cytologic score of 17, representing a sensitivity of 83% and a specificity of 81%.
  • For distinguishing histologic Grade 3 from the others, the best cut-off value was a cytologic score of 20, representing a sensitivity of 100% and a specificity of 83%.
  • CONCLUSIONS: The cytologic scoring system studied for endometrioid adenocarcinoma was useful for predicting histologic grade and tumor malignant potential.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 American Cancer Society
  • (PMID = 15597380.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


38. Rice LW, Stone RL, Xu M, Galgano M, Stoler MH, Everett EN, Jazaeri AA: Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors. Am J Obstet Gynecol; 2006 Apr;194(4):1119-26; discussion 1126-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors.
  • OBJECTIVE: The purpose of this study was to investigate the AKT signaling cascade in endometrial cancers and to assess its therapeutic potential.
  • STUDY DESIGN: Western blotting and immunohistochemistry were used to investigate the expression of estrogen receptor, progesterone receptor, HER2, AKT, and 4EBP1 proteins in 27 atrophic endometria, 31 grade 1 and 24 grade 3 endometrioid endometrial cancers, and 19 malignant mixed müllerian tumors.
  • RESULTS: Malignant mixed müllerian tumors and grade 3 endometrioid endometrial cancers demonstrated higher levels of AKT and 4EBP1 activation and hormone receptor loss compared with grade 1 endometrioid endometrial cancers and atrophic samples.
  • In endometrial cancer cell-lines, AKT cascade inhibitors decreased cell proliferation by apoptosis and cell cycle arrest.
  • CONCLUSION: AKT cascade activation in grade 3 endometrioid endometrial cancers and malignant mixed müllerian tumors is a novel finding.
  • [MeSH-major] Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Mixed Tumor, Mullerian / drug therapy. Oncogene Protein v-akt / antagonists & inhibitors

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580307.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA44579
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / Oncogene Protein v-akt
  •  go-up   go-down


39. Nishimura N, Hachisuga T, Yokoyama M, Iwasaka T, Kawarabayashi T: Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary. J Obstet Gynaecol Res; 2005 Apr;31(2):120-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary.
  • AIM: To compare the survival and prognostic factors of patients with dual primary ovarian and endometrial cancers (primary group), and endometrial cancers metastatic to the ovaries (metastatic group).
  • METHODS: Thirty-six patients with gross tumors confined to the pelvis and of endometrioid adenocarcinoma subtype in both the endometrium and ovary were selected from our file of 546 Japanese women with endometrial carcinoma.
  • Univariate analyses showed that older age (P < 0.05) and the presence of lymphovascular space invasion (LVSI; P < 0.004) of the tumor of the uterus were significantly associated with a poor prognosis in the metastatic group.
  • CONCLUSION: When encountering women with coexisting endometrioid carcinoma in the endometrium and ovary with gross tumor limited to the pelvis, more attention should be paid to LVSI of the tumor of the uterus as a poor prognostic indicator.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771637.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Klopfleisch R, van der Grinten E, Gruber AD: Metastatic uterine adenocarcinoma and hepatic lipomatosis in a llama (Lama glama). J Vet Diagn Invest; 2009 Mar;21(2):280-2
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic uterine adenocarcinoma and hepatic lipomatosis in a llama (Lama glama).
  • Postmortem examination revealed an infiltrative uterine adenocarcinoma with widespread metastases.
  • The neoplasm completely replaced and infiltrated the myometrium of the uterine body and cervix and metastasized largely to the serosal surfaces of the peritoneal cavity.
  • [MeSH-major] Adenocarcinoma / veterinary. Camelids, New World. Lipomatosis / veterinary. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary. Uterine Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19286516.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Viral Proteins
  •  go-up   go-down


46. Boutet G: [Levonorgestrel-releasing intrauterine device (Mirena) and breast cancer: what do we learn from literature for clinical practice?]. Gynecol Obstet Fertil; 2006 Nov;34(11):1015-23
Hazardous Substances Data Bank. LEVONORGESTREL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Levonorgestrel-releasing intrauterine device (Mirena) and breast cancer: what do we learn from literature for clinical practice?].
  • [Transliterated title] Dispositif intra-utérin au lévonorgestrel (Mirena) et cancer du sein: que nous apporte la littérature pour la pratique quotidienne?
  • Annual occurrence of breast cancer is constantly increasing in France.
  • In 2000, the number of breast cancer cases for women of 30-49 years was estimated at 9,918, which represents 23.7% of all breast cancer cases diagnosed that year.
  • Because contraception is an important matter for women whose ovarian function survived cancer treatments, the question of whether to use such device on a woman with breast cancer has become a frequent and controversial gynaecological issue.
  • First, whether the use of IUD LNG increases the risk of breast cancer: there is at the moment no "A" level answer available.
  • Second, whether the use of IUD LNG counterbalances the endometrial effects of Tamoxifene: based on a limited level of evidence via a single randomised controlled trial on a small number of patients for one year only, this device appears to be able to prevent benign endometrial modifications.
  • However, there is no conclusive study regarding its effectiveness on the prevention of endometrium adenocarcinoma caused by Tamoxifene.
  • Third, whether a woman with a personal antecedent of breast cancer can safely use DIU LNG: it is necessary to remove it promptly upon suspicion or diagnosis, to dissuade its use in case of current cancer, and, in the event of cancer remission for more than 5 years, to generally avoid this contraceptive method except on a case by case basis and with a regular medical follow-up.
  • [MeSH-minor] Adenocarcinoma / prevention & control. Adult. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / prevention & control. Evidence-Based Medicine. Female. France / epidemiology. Humans. Middle Aged. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17092752.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Contraceptive Agents, Female; 094ZI81Y45 / Tamoxifen; 5W7SIA7YZW / Levonorgestrel
  • [Number-of-references] 59
  •  go-up   go-down


47. Marchesoni D, Driul L, Mozzanega B, Nardelli GB, Parenti A: Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment. Arch Gynecol Obstet; 2005 Jan;271(1):62-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment.
  • CASE REPORT: In this paper we describe a case of endometrial carcinoma observed in a post-menopausal patient who was treated with tamoxifen for 5 years after a mastectomy for cancer.
  • TREATMENT: She underwent hysteroscopy and a D and C.
  • A polypoid endometrium completely filled the uterine cavity and was carefully removed by curettage; histology showed a highly undifferentiated neoplasia with a component of serous adenocarcinoma, which was likely to originate from endometrial polyps.
  • OUTCOME: The patient underwent radical hysterectomy, but no residual tumor was found in the uterus or in the tubes, ovary, or pelvic nodes, in spite of its low differentiation grade and high potential aggressiveness, and even though the patient was already symptomatic.
  • [MeSH-major] Adenocarcinoma / chemically induced. Anticarcinogenic Agents / adverse effects. Antineoplastic Agents, Hormonal / adverse effects. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / surgery. Chemotherapy, Adjuvant. Dilatation and Curettage. Endometrium / drug effects. Endometrium / pathology. Female. Humans. Hysteroscopy. Mastectomy, Radical. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15290168.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


48. Hsu MI, Chou SY, Lin SE, Liang SJ, Chiu HC, Hsu CS: Very early stage adenocarcinoma arising from adenomyosis in the uterus. Taiwan J Obstet Gynecol; 2006 Dec;45(4):346-9
MedlinePlus Health Information. consumer health - Uterine Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very early stage adenocarcinoma arising from adenomyosis in the uterus.
  • OBJECTIVE: Malignant transformations of adenomyosis in premenopausal women with normal endometrium are extremely rare.
  • We report a case of adenocarcinoma arising from an adenomyotic focus in the uterus, which was found unexpectedly in a woman undergoing myomectomy for adenomyosis.
  • She was admitted and underwent myomectomy under the initial diagnosis of uterine leiomyoma.
  • Microscopic studies revealed endometrioid adenocarcinoma, which was a malignant transformation of a focus of adenomyosis in the surgical specimen.
  • The endometrium had normal thickness with mild proliferative activity throughout the cavity.
  • There was no atrophic or hyperplastic change in the whole endometrium.
  • The adenocarcinoma was present exclusively in the myometrium, and a transition between the carcinoma and the adenomyotic glands was observed.
  • CONCLUSION: This case report presents evidence that adenocarcinoma may a rise de novo from an adenomyotic lesion in the uterus.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Endometriosis / surgery. Uterine Diseases / surgery
  • [MeSH-minor] Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. Middle Aged. Myometrium / pathology. Premenopause

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175497.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Akbulut M, Tosun H, Soysal ME, Oztekin O: Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature. Arch Gynecol Obstet; 2008 Jul;278(1):79-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature.
  • OBJECTIVE: An endometrioid adenocarcinoma (EAC) with true trophoblastic differentiation is a rare event with a highly aggressive clinical course.
  • CASE: We report an endometrioid adenocarcinoma of the endometrium in which there was a morphologically conventional-appearing EAC component admixed with multinucleated giant cells and large pleomorphic tumor cells that resembled a choriocarcinoma without an elevated serum level of human chorionic gonadotropin (hCG) in a 42-year-old unmarried woman with a history of abnormal uterine bleeding.
  • Histopathologic study of the specimen showed endometrioid adenocarcinoma extended to the deep myometrium with a focus of hemorrhagic and necrotic tumor composed of multinucleated giant cells, large pleomorphic tumor cells, suggesting choriocarcinomatous differentiation (CD).
  • Immunohistochemical studies demonstrated intense reactivity of tumor cells for human chorionic gonadotropin (hCG) confirming the diagnosis.
  • CONCLUSION: Although endometrioid adenocarcinoma with choriocarcinomatous differentiation is known to behave in a more aggressive course, this disease may have a good prognosis with a clinically indolent course when it is small, and without elevated serum hCG levels.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Choriocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18066564.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  • [Number-of-references] 24
  •  go-up   go-down


50. Bewtra C, Xie QM, Hunter WJ, Jurgensen W: Ichthyosis uteri: a case report and review of the literature. Arch Pathol Lab Med; 2005 May;129(5):e124-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous metaplasia of endometrium is mostly manifested by morules or nodules of benign nonkeratinizing squamous cells intimately mixed with benign or malignant endometrial glands.
  • It has been described with low-grade adenocarcinoma of the endometrium, as well as with various benign conditions, including hyperplasia, chronic endometritis, and endometrial polyps.
  • To our knowledge, we describe the first case of extensive benign squamous keratinization with underlying endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ichthyosis / diagnosis. Uterus / pathology

  • Genetic Alliance. consumer health - Ichthyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859657.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


51. Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T: Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res; 2005 Nov-Dec;25(6B):4101-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.
  • Matrix metalloproteinase-2 (MMP-2), a member of the zinc-dependent metalloproteinase gene family, plays an important role in cancer invasion and metastasis.
  • The current study aimed to evaluate whether the expression of MMP-2 is associated with survival in patients with endometrial endometrioid adenocarcinoma.
  • The MMP-2 immunoreactive protein was evaluated from endometrioid adenocarcinoma of the endometrium in 112 patients treated at Oulu University Hospital, Finland.
  • These data suggest that MMP-2 immunostaining negativity might be linked with a favourable prognosis in endometrial endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / enzymology. Endometrial Neoplasms / enzymology. Matrix Metalloproteinase 2 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309203.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


52. Rauh-Hain JA, Costaaggini I, Olawaiye AB, Growdon WB, Horowitz NS, del Carmen MG: A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy. Eur J Gynaecol Oncol; 2010;31(3):284-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy.
  • OBJECTIVE: To determine the outcomes in patients with Stage I uterine clear cell carcinoma (UCCC) treated with and without adjuvant therapy, and to compare the outcomes in these patients to that of matched controls, patients with Stage I, grade 3, endometrioid adenocarcinoma of the endometrium (EC).
  • Cases (UCCC) were matched by age, stage, adjuvant therapy, and year of diagnosis to controls consisting of patients with grade 3 EC.
  • These data question the benefit of radiation therapy in UCCC patients with disease confined to the uterus.
  • [MeSH-major] Adenocarcinoma, Clear Cell / therapy. Carcinoma, Endometrioid / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Case-Control Studies. Chemotherapy, Adjuvant. Endometrial Neoplasms. Female. Humans. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21077469.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


53. Zamecnik M, Sokol L, Michal M: Low-grade metaplastic adenocarcinoma (carcinosarcoma) of the uterus: report of an unusual case. Ann Diagn Pathol; 2005 Dec;9(6):335-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade metaplastic adenocarcinoma (carcinosarcoma) of the uterus: report of an unusual case.
  • An unusual low-grade metaplastic carcinoma (müllerian carcinosarcoma) of the uterine corpus occurring in a 45-year-old woman is presented.
  • The epithelial component was composed of low-grade endometrioid glands that focally showed an unusual oxyphilic change of the cytoplasm.
  • An invasive marginal zone of the tumor showed endometrioid adenocarcinoma pattern without any stromal component.
  • [MeSH-major] Carcinosarcoma / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Female. Humans. Metaplasia / pathology. Middle Aged. Myometrium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308164.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Wong WL, Tay EH: Adenocarcinoma of the abdominal wall. Singapore Med J; 2008 Dec;49(12):e359-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the abdominal wall.
  • We report a rare case of adenocarcinoma confined to the umbilicus.
  • Excision biopsy showed adenocarcinoma with an appearance suggestive of metastasis from an ovarian cystadenocarcinoma.
  • The frozen section of the tumour showed papillary adenocarcinoma.
  • Histology showed adenocarcinoma favouring serous cancer.
  • There was no tumour seen in the ovaries, uterus and omentum.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Abdominal Wall. Adenocarcinoma, Papillary / diagnosis
  • [MeSH-minor] Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / secondary. Diagnosis, Differential. Female. Humans. Middle Aged. Ovarian Neoplasms / pathology. Umbilicus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122935.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


55. Hayasaka T, Nakahara K, Kojimahara T, Saito-Sekiguchi M, Motoyama T, Kurachi H: Endometrioid adenocarcinoma with a functioning stroma. J Obstet Gynaecol Res; 2007 Jun;33(3):381-3
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma with a functioning stroma.
  • A case of a 70-year-old woman with endometrioid adenocarcinoma of the ovary with functioning stroma is presented.
  • The endometrial tissue showed hyperplastic changes.
  • The surgical specimens consisted of a multilocular cystic ovarian tumor of 95 mm in diameter and an enlarged uterus.
  • Histologically, the tumor was composed of proliferating, atypical, columnar cancer cells resembling early secretory endometrial cells, and condensation of plumed stromal cells resembling theca lutein cells.
  • The diagnosis of endometrial adenocarcinoma of the ovary with functioning stroma was made.
  • Mucinous epithelial ovarian tumors most commonly present with estrogenic stroma, although the frequency of endometrioid adenocarcinoma with functioning stroma is very low.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Estradiol / blood. Follicle Stimulating Hormone / blood. Ovarian Neoplasms / pathology. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578372.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


56. Pires MA, Seixas F, Palmeira C, Payan-Carreira R: Histopathologic and immunohistochemical exam in one case of canine endometrial adenocarcinoma. Reprod Domest Anim; 2010 Jun;45(3):545-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic and immunohistochemical exam in one case of canine endometrial adenocarcinoma.
  • Canine endometrial carcinomas are rare, and mostly occur in geriatric bitches.
  • In this work, the uterus of a 10-year-old female Boxer evidencing an endometrial carcinoma on the body of the uterus was used to describe the histopathological features of the tumour and to study its immunophenotype.
  • In this work, a panel of immunomarkers (cytokeratins AE1/AE3 and 14, vimentin, CD10 and Ki-67) was applied to the endometrial carcinoma to establish the staining patterns indicative of the tumour agressiveness and cellular differentiation.
  • This study aims to contribute to the advancement of the knowledge in canine endometrial carcinoma immunophenotype.
  • [MeSH-major] Adenocarcinoma / veterinary. Dog Diseases / diagnosis. Endometrial Neoplasms / veterinary. Immunohistochemistry / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144037.001).
  • [ISSN] 1439-0531
  • [Journal-full-title] Reproduction in domestic animals = Zuchthygiene
  • [ISO-abbreviation] Reprod. Domest. Anim.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Vimentin; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


57. Desrosiers L, Fadare O, Xiao ZF, Dresser K, Wang SA: Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium. Ann Diagn Pathol; 2008 Apr;12(2):112-7
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium.
  • This study was conducted to determine whether, in a pure population of patients with International Federation of Gynecology and Obstetrics stage I endometrioid endometrial (S1EE) carcinoma that is confined to the uterus and without lymph node metastases, the presence of lymphovascular space invasion (LVSI) is positively associated with vaginal relapses.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Vaginal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325471.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • OBJECTIVE: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • Cytology of the pleural effusion showed no malignant cells.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • Endocervical adenocarcinoma, < 3 mm in depth, was also identified on the cervix.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175478.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


59. Naciff JM, Khambatta ZS, Thomason RG, Carr GJ, Tiesman JP, Singleton DW, Khan SA, Daston GP: The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci; 2009 Jan;107(1):40-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol.
  • We have determined the gene expression profile induced by 17 alpha-ethynyl estradiol (EE) in Ishikawa cells, a human uterine-derived estrogen-sensitive cell line, at various doses (1 pM, 100 pM, 10 nM, and 1 microM) and time points (8, 24, and 48 h).
  • All of these processes are also affected by estrogen exposure in the uterus of the rat.
  • Comparison of the response to EE in both the rat uterus and the Ishikawa cells showed that 71 genes are regulated in a similar manner in vivo as well as in vitro.
  • [MeSH-major] Ethinyl Estradiol / pharmacology. Gene Expression / drug effects. Uterus / metabolism
  • [MeSH-minor] Animals. Cell Line. Databases, Genetic. Dose-Response Relationship, Drug. Female. Gene Expression Profiling. Genes / genetics. Genes / physiology. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / analysis. Rats. Time Factors. Transforming Growth Factor alpha / genetics. Transforming Growth Factor alpha / metabolism. Uterine Neoplasms / metabolism

  • Hazardous Substances Data Bank. ETHINYLESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936297.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Transforming Growth Factor alpha; 423D2T571U / Ethinyl Estradiol
  •  go-up   go-down


60. Kazandi M, Zeybek B, Terek MC, Zekioglu O, Ozdemir N, Oztekin K: Grade 2 endometrioid adenocarcinoma arising from adenomyosis of the uterus: report of a case. Eur J Gynaecol Oncol; 2010;31(6):719-21
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grade 2 endometrioid adenocarcinoma arising from adenomyosis of the uterus: report of a case.
  • Adenomyosis is defined by the presence of endometrial tissue (glands and stroma) within the myometrium and malignant transformation of adenomyosis in premenopausal women with normal endometrium is extremely rare.
  • Adenocarcinomas arising within adenomyosis need to be distinguished from endometrial carcinomas which arise from the eutopic endometrium, then extend into preexisting adenomyosis of the uterine wall.
  • We report a case of grade 2 endometrioid adenocarcinoma arising from an adenomyotic focus in the uterus.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology

  • Genetic Alliance. consumer health - Adenomyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319528.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


61. Takacs P, De Santis T, Nicholas MC, Verma U, Strassberg R, Duthely L: Echogenic endometrial fluid collection in postmenopausal women is a significant risk factor for disease. J Ultrasound Med; 2005 Nov;24(11):1477-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Echogenic endometrial fluid collection in postmenopausal women is a significant risk factor for disease.
  • OBJECTIVE: The purpose of this study was to assess postmenopausal women with endometrial fluid collection and the risk of significant endometrial or cervical disease.
  • METHODS: A retrospective chart review was conducted of 343 postmenopausal women with endometrial fluid collection on pelvic sonography.
  • Medical records were reviewed to identify women who underwent an evaluation of the endometrium with endometrial biopsy, hysteroscopy, or hysterectomy after the sonographic examination.
  • Clinical and sonographic characteristics were compared between women with diagnoses of cervical or endometrial cancer or hyperplasia (nonbenign group) and women with benign conditions (benign group).
  • RESULTS: The endometrium was significantly thicker in the nonbenign group compared with the benign group (mean +/- SD, 9.9 +/- 7.4 versus 5.9 +/- 4.1 mm; P = .016).
  • None of the patients with adenocarcinoma of the endometrium had endometrial thickness of 3 mm or less, but 2 with endocervical cancer did.
  • Echogenic fluid in the endometrial cavity was significantly more likely to be found in the nonbenign group compared with the benign group (45.8% versus 4.8%; P < .01).
  • Multivariate logistic regression analysis revealed that echogenic fluid in the endometrial cavity was the only significant risk factor for nonbenign conditions (odds ratio, 10.94; 95% confidence interval, 2.67-44.84; P < .01).
  • CONCLUSIONS: Postmenopausal women with endometrial fluid collection on sonography should undergo endometrial sampling if the endometrial lining is thicker than 3 mm or the endometrial fluid is echogenic.
  • If the lining is 3 mm or less and the endometrial fluid is clear, endometrial sampling is not necessary, but we recommend endocervical sampling to rule out endocervical cancer.
  • [MeSH-major] Endometrium. Postmenopause. Uterine Cervical Diseases / ultrasonography
  • [MeSH-minor] Body Fluids. Female. Humans. Middle Aged. Retrospective Studies. Risk Factors. Uterine Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16239648.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Miyakuni Y, Matsumoto T, Arakawa A, Sonoue H, Suzuki C, Takeda S: Lymphatic invasion according to D2-40 immunostaining is a predictor of nodal metastasis in endometrioid adenocarcinoma of the uterine corpus. Pathol Int; 2008 Aug;58(8):471-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic invasion according to D2-40 immunostaining is a predictor of nodal metastasis in endometrioid adenocarcinoma of the uterine corpus.
  • In endometrioid adenocarcinoma of the uterine corpus, nodal metastasis is related to prognosis.
  • D2-40 immunostaining has recently been used to detect lymphatic invasion, but a study of D2-40 immunostaining for endometrioid adenocarcinoma of the uterine corpus has not been published.
  • Therefore, as a predictor of nodal metastasis in endometrioid adenocarcinoma of the uterine corpus, the detection of lymphatic invasion on D2-40 immunostaining and lymphovascular invasion on HE stain was compared.
  • A total of 104 cases of invasive endometrioid adenocarcinoma of the uterine corpus, in which the tumor was located in the uterus, were examined on immunohistochemistry using D2-40.
  • In conclusion, lymphatic invasion demonstrated on D2-40 immunostaining is very useful as a predictor for nodal metastasis in endometrioid adenocarcinoma of uterine corpus.
  • [MeSH-major] Antibodies, Monoclonal / analysis. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / secondary. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705765.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


63. Wicherek L, Popiela TJ, Galazka K, Dutsch-Wicherek M, Opławski M, Basta A, Klimek M: Metallothionein and RCAS1 expression in comparison to immunological cells activity in endometriosis, endometrial adenocarcinoma and endometrium according to menstrual cycle changes. Gynecol Oncol; 2005 Dec;99(3):622-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein and RCAS1 expression in comparison to immunological cells activity in endometriosis, endometrial adenocarcinoma and endometrium according to menstrual cycle changes.
  • OBJECTIVE: Endometrium is a specialized organ in which phenomena controlling the level of cell proliferation and apoptosis are marked.
  • The aim of our study was to determine the presence of proteins involved in apoptosis and proliferation: RCAS1, MT and the number of CD56-positive cells and their activity to elucidate their possible role in the development of adenocarcinoma and endometriosis.
  • RESULTS: We found that endometrium during secretory menstrual cycle phase is characterized by significantly higher RCAS1 and higher MT expression than in proliferative phase.
  • Endometrial adenocarcinoma was characterized by significantly increased RCAS1 expression, while MT expression was comparable to the level found in the secretory phase.
  • CONCLUSIONS: The ability of endometrium to determine cytotoxic activity (RCAS1 expression changes) and high protection against DNA damage (MT expression) with concomitant changes in the number of immune cells and their activity, observed in normal endometrium during the menstrual cycle phases seems to be fundamental for pathological features of endometrial adenocarcinoma and endometriosis.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, Neoplasm / biosynthesis. Endometrial Neoplasms / immunology. Endometriosis / immunology. Endometrium / immunology. Menstrual Cycle / immunology. Metallothionein / biosynthesis

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112719.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / CD69 antigen; 0 / EBAG9 protein, human; 0 / Lectins, C-Type; 9038-94-2 / Metallothionein
  •  go-up   go-down


64. Jeong JW, Lee HS, Franco HL, Broaddus RR, Taketo MM, Tsai SY, Lydon JP, DeMayo FJ: beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus. Oncogene; 2009 Jan 08;28(1):31-40
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus.
  • Endometrioid adenocarcinoma is the most frequent form of endometrial cancer, usually developing in pre- and peri-menopausal women. beta-catenin abnormalities are common in endometrioid type endometrial carcinomas with squamous differentiation.
  • To investigate the role of beta-catenin (Ctnnb1) in uterine development and tumorigenesis, mice were generated which expressed a dominant stabilized beta-catenin or had beta-catenin conditionally ablated in the uterus by crossing the PR(Cre) mouse with the Ctnnb1(f(ex3)/+) mouse or Ctnnb1(f/f) mouse, respectively.
  • Both of the beta-catenin mutant mice have fertility defects and the ability of the uterus to undergo a hormonally induced decidual reaction was lost.
  • Expression of the dominant stabilized beta-catenin, PR(cre/+)Ctnnb1(f(ex3)/+), resulted in endometrial glandular hyperplasia, whereas ablation of beta-catenin, PR(cre/+)Ctnnb1(f/f), induced squamous cell metaplasia in the murine uterus.
  • Therefore, we have demonstrated that correct regulation of beta-catenin is important for uterine function as well as in the regulation of endometrial epithelial differentiation.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Endometrial Hyperplasia / genetics. Endometrium / growth & development. beta Catenin / physiology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Feb 4;397(6718):405-9 [9989404.001]
  • [Cites] Endocrinology. 1999 Jan;140(1):484-91 [9886861.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1442-4 [10197610.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1811-5 [10213482.001]
  • [Cites] Int Immunol. 1999 Mar;11(3):317-23 [10221643.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7 [10318916.001]
  • [Cites] Mol Endocrinol. 1999 Jun;13(6):1005-17 [10379898.001]
  • [Cites] Mol Carcinog. 1999 Jul;25(3):207-18 [10411147.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3346-51 [10416591.001]
  • [Cites] J Reprod Fertil. 1964 Dec;8:331-8 [14248593.001]
  • [Cites] Mol Endocrinol. 2004 Dec;18(12):3035-49 [15358837.001]
  • [Cites] Hum Pathol. 2004 Nov;35(11):1360-8 [15668893.001]
  • [Cites] Genesis. 2005 Feb;41(2):58-66 [15682389.001]
  • [Cites] Arch Histol Cytol. 2004 Dec;67(5):417-34 [15781983.001]
  • [Cites] Lab Invest. 2005 Jun;85(6):768-79 [15806138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8579-84 [15930138.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):605-19 [16021566.001]
  • [Cites] Dev Biol. 2005 Dec 1;288(1):276-83 [16256976.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):811-6 [16804722.001]
  • [Cites] FEBS Lett. 2006 Oct 16;580(24):5653-60 [17011554.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):269-73 [17224652.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):240-5 [17297296.001]
  • [Cites] J Invest Dermatol. 2007 May;127(5):1175-86 [17159913.001]
  • [Cites] Dev Biol. 2007 Jul 15;307(2):227-36 [17532316.001]
  • [Cites] Mol Cell Biol. 2007 Aug;27(15):5468-78 [17515606.001]
  • [Cites] Trends Endocrinol Metab. 2007 Aug;18(6):234-9 [17588769.001]
  • [Cites] J Histochem Cytochem. 2007 Sep;55(9):963-74 [17533218.001]
  • [Cites] J Biol Chem. 2007 Oct 26;282(43):31725-32 [17711857.001]
  • [Cites] Annu Rev Pathol. 2007;2:57-85 [18039093.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):567-78 [10662781.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):323-6 [10671680.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):209-17 [11161379.001]
  • [Cites] J Pathol. 2001 Jan;193(1):95-101 [11169521.001]
  • [Cites] Development. 2001 Apr;128(8):1253-64 [11262227.001]
  • [Cites] J Pathol. 2001 May;194(1):59-67 [11329142.001]
  • [Cites] Oncogene. 2002 Nov 14;21(52):7981-90 [12439748.001]
  • [Cites] Yonsei Med J. 2002 Dec;43(6):701-11 [12497652.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):577-88 [14742263.001]
  • [Cites] Development. 2004 May;131(9):2061-72 [15073149.001]
  • [Cites] Mol Endocrinol. 2004 May;18(5):1238-50 [14976223.001]
  • [Cites] Biol Reprod. 2004 Aug;71(2):444-54 [15070830.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1260-5 [15492994.001]
  • [Cites] J Endocrinol. 1973 Jan;56(1):133-44 [4683406.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Mol Endocrinol. 1988 Dec;2(12):1243-8 [3216864.001]
  • [Cites] Endocrinology. 1989 Sep;125(3):1683-90 [2667965.001]
  • [Cites] J Biol Chem. 1989 Oct 5;264(28):16941-7 [2674144.001]
  • [Cites] Nature. 1992 Sep 3;359(6390):76-9 [1522892.001]
  • [Cites] Development. 1995 Nov;121(11):3529-37 [8582267.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):143-4 [9326929.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4736-8 [9354433.001]
  • [Cites] Development. 1998 Aug;125(16):3201-11 [9671592.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3526-8 [9721853.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Nature. 1998 Oct 15;395(6703):707-10 [9790192.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3005-10 [9865913.001]
  • [Cites] Jpn J Cancer Res. 1999 Jan;90(1):55-9 [10076565.001]
  • (PMID = 18806829.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01HD057873; United States / NICHD NIH HHS / HD / U54 HD007495-359009; United States / NICHD NIH HHS / HD / U54 HD007495-359022; United States / NCI NIH HHS / CA / R01 CA077530-09; United States / NICHD NIH HHS / HD / U54 HD007495-350006; United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCI NIH HHS / CA / P50 CA098258-019001; United States / NICHD NIH HHS / HD / U54HD28934; United States / NICHD NIH HHS / HD / R03 HD077495; United States / NCI NIH HHS / CA / P50 CA098258; United States / NICHD NIH HHS / HD / U54 HD028934; United States / NICHD NIH HHS / HD / U54HD0077495; United States / NICHD NIH HHS / HD / R01 HD057873-01; United States / NICHD NIH HHS / HD / R01 HD042311-06A1; United States / NCI NIH HHS / CA / R01 CA077530; United States / NICHD NIH HHS / HD / U54 HD007495; United States / NICHD NIH HHS / HD / R01 HD042311; United States / NICHD NIH HHS / HD / R01HD042311; United States / NCI NIH HHS / CA / P50 CA083639-099005; United States / NCI NIH HHS / CA / R01-CA77530; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA098258-010003; United States / NICHD NIH HHS / HD / R01 HD057873
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, mouse; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS88308; NLM/ PMC2646831
  •  go-up   go-down


65. Acién P, Acién M, Sánchez-Ferrer ML: Müllerian anomalies "without a classification": from the didelphys-unicollis uterus to the bicervical uterus with or without septate vagina. Fertil Steril; 2009 Jun;91(6):2369-75
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Müllerian anomalies "without a classification": from the didelphys-unicollis uterus to the bicervical uterus with or without septate vagina.
  • PATIENT(S): Six women with uterine malformation.
  • RESULT(S): We have included examples of cases presenting with didelphys uterus with normal cervix, didelphys uterus with septate cervix, and bicornuate (or didelphys) uterus with septate cervix and vagina versus septate uterus with double cervix and vagina, septate bicervical uterus with isthmic communication, and normal simplex uterus with septate cervix and vagina.
  • Therefore, for a more appropriate classification of the uterine malformations, even if the same degrees of fusion, resorption, and development defects are used, a separate classification should be made for each superior and inferior uterine segment.
  • [MeSH-major] Cervix Uteri / abnormalities. Mullerian Ducts / abnormalities. Uterus / abnormalities. Vagina / abnormalities
  • [MeSH-minor] Abnormalities, Multiple / surgery. Adenocarcinoma / surgery. Adult. Aged. Cesarean Section. Female. Humans. Hysterectomy. Middle Aged. Pregnancy. Reproductive Techniques, Assisted. Uterine Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367185.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, Dodson WC: The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol; 2007 Apr;196(4):402.e1-10; discussion 402.e10-1
Hazardous Substances Data Bank. ROSIGLITAZONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.
  • OBJECTIVE: To examine the effects of metformin and rosiglitazone, alone and in combination, on endometrial histology and ovarian steroid production.
  • RESULTS: Abnormal endometrial histology was found in 3 subjects at baseline, including 1 case of adenocarcinoma of the endometrium in an asymptomatic subject, who was excluded from further study.
  • CONCLUSION: This study provides preliminary evidence that insulin-sensitizing drugs may have beneficial effects on the endometrium, although the exact mechanism beyond improving ovulatory function is still unknown.
  • [MeSH-major] Endometrium / pathology. Metformin / therapeutic use. Ovary / pathology. Polycystic Ovary Syndrome / drug therapy. Thiazolidinediones / therapeutic use

  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403436.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR016499; United States / NICHD NIH HHS / HD / K24 HD001476; United States / NCRR NIH HHS / RR / M01 RR010732
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone; 9100L32L2N / Metformin
  •  go-up   go-down


67. Mendivil A, Schuler KM, Gehrig PA: Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control; 2009 Jan;16(1):46-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes.
  • BACKGROUND: Understanding the etiology, presentation, evaluation, and management of selected non-endometrioid endometrial adenocarcinomas of the uterine corpus is needed to define optimal treatment regimens.
  • METHODS: The pathology and treatment of selected non-endometrioid endometrial adenocarcinomas of the uterus are reviewed and summarized.
  • RESULTS: The most common non-endometrioid histology is papillary serous (10%), followed by clear cell (2% to 4%), mucinous (0.6% to 5%), and squamous cell (0.1% to 0.5%).
  • Some non-endometrioid endometrial carcinomas behave more aggressively than the endometrioid cancers such that even women with clinical stage I disease often have extrauterine metastasis at the time of surgical evaluation.
  • Therefore, when technically and medically feasible, comprehensive surgical staging is helpful for women with non-endometrioid endometrial cancer histology.
  • While whole abdominal radiotherapy has a limited role in early-stage uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CC), there may be a role for postoperative chemotherapy and volume-directed radiotherapy in both early-stage UPSC and CC.
  • In the setting of recurrent disease or in women with residual disease after surgery, a platinum-based regimen or enrollment in a clinical trial is recommended.
  • The remaining cell types should be treated similar to endometrioid or other low-grade histologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078929.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 51
  •  go-up   go-down


68. Brown L: Pathology of uterine malignancies. Clin Oncol (R Coll Radiol); 2008 Aug;20(6):433-47
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of uterine malignancies.
  • This overview covers epithelial, stromal and mesenchymal malignancies of the body of the uterus, excluding the cervix.
  • The distinction of type I and type II endometrial adenocarcinoma with the morphological variants of this tumour is discussed and some molecular aspects are explored.
  • The concept of carcinosarcoma representing a metaplastic adenocarcinoma of the endometrium that behaves more like a carcinoma than a sarcoma is explained.
  • The concept of stromal sarcoma and high-grade uterine sarcoma is described and an outline of malignant smooth muscle tumours of the uterus includes a description of smooth muscle tumours of uncertain malignant potential and worrying benign smooth muscle lesions.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Endometrial Stromal Tumors / pathology. Female. Humans. Leiomyosarcoma / pathology. Mesoderm / pathology. Neoplasms, Glandular and Epithelial / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499412.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 233
  •  go-up   go-down


69. Yamada K, Kano J, Tsunoda H, Yoshikawa H, Okubo C, Ishiyama T, Noguchi M: Phenotypic characterization of endometrial stromal sarcoma of the uterus. Cancer Sci; 2006 Feb;97(2):106-12
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic characterization of endometrial stromal sarcoma of the uterus.
  • Endometrial stromal sarcoma (ESS) of the uterus is a rare uterine malignancy that has not been characterized in detail.
  • To characterize the phenotype of ESS of the uterus, we extracted RNA from ESS and the stroma of normal endometrium using a tissue microdissection system and compared the expression profiles in the two tissues.
  • After suppression subtractive hybridization and differential screening, we detected the metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) gene as one of the major genes upregulated in ESS, and a full-length placental cDNA clone (CS0DI066YJ10) as one of the major genes downregulated.
  • The results were confirmed by in situ hybridization in four resected specimens of ESS and 36 biopsy specimens of normal endometrial tissue.
  • All ESS (4/4) and all cases of endometrial stromal cells in the proliferative phase (13/13) were positive for MALAT-1, but samples of normal stroma in the secretory phase and menopausal state included some that were negative or weakly positive for MALAT-1 (5/13 and 3/10, respectively).
  • In contrast, all ESS and 12 of 13 cases of stromal cells in the proliferative phase were negative for the full-length placental cDNA clone but 10 of 13 cases of endometrial stromal cells in the secretory phase were positive for transcripts of the gene (P < 0.05).
  • These results indicated that endometrial stromal cells have different phenotypic characteristics between proliferative and secretory phases and the tumor cells of ESS have the phenotypic character of endometrial stromal cells in the proliferative phase.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Neoplasm Proteins / metabolism. Sarcoma, Endometrial Stromal / metabolism. Uterine Neoplasms / metabolism
  • [MeSH-minor] Cell Proliferation. Endometrium / metabolism. Endometrium / pathology. Female. Gene Expression Profiling. Humans. In Situ Hybridization. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Middle Aged. Nucleic Acid Hybridization. Phenotype. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Retroperitoneal Neoplasms / metabolism. Retroperitoneal Neoplasms / secondary. Stromal Cells / metabolism. Stromal Cells / pathology. Subtraction Technique. Uterus / metabolism. Uterus / pathology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16441420.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Neoplasm
  •  go-up   go-down


70. Kernochan LE, Garcia RL: Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw; 2009 May;7(5):550-6; quiz 557
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics.
  • Carcinosarcoma of the uterus (malignant mixed Müllerian tumor [MMMT]) is an uncommon, typically extremely aggressive neoplasm histologically composed of malignant epithelial and mesenchymal (stromal) elements.
  • Although the literature contains some debate, most authors now agree that most MMMTs derive from sarcomatous differentiation in a high-grade carcinoma.
  • This article reviews the clinical and histopathologic features of this interesting neoplasm, with particular emphasis on recent data supporting MMMTs as primarily epithelial malignant neoplasms with areas of mesenchymal/spindle cell differentiation.
  • [MeSH-major] Carcinosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Female. Humans. Immunohistochemistry. Loss of Heterozygosity. Neoplasm Metastasis. Prognosis

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460280.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


71. Vaccaro CA, Bonadeo F, Roverano AV, Peltomaki P, Bala S, Renkonen E, Redal MA, Mocetti E, Mullen E, Ojea-Quintana G, Benati ML, Rivello HG, Clark MB, Lynch JF, Lynch HT: Hereditary nonpolyposis colorectal cancer (Lynch Syndrome) in Argentina: report from a referral hospital register. Dis Colon Rectum; 2007 Oct;50(10):1604-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hereditary nonpolyposis colorectal cancer (Lynch Syndrome) in Argentina: report from a referral hospital register.
  • Among the 306 affected members, 197 cases of colorectal cancer were identified (mean age at diagnosis, 52.1 (range, 21-90) years).
  • The most frequent extracolonic tumors were gastric adenocarcinoma in males and endometrium adenocarcinoma in females.
  • A high incidence of breast cancer was observed (16 cases among 155 females, crude rate: 11,594.20/100,000).
  • A novel C deletion at 1910 nucleotide, codon 637, exon 12 of MSH2 gene was identified in a family with a strong aggregation of breast cancer with lack of MSH2 immunohistochemical staining.
  • CONCLUSIONS: Argentine families presented a high incidence of stomach cancer.
  • The elevated incidence of breast cancer and its association with a novel hMSH2 mutation bring to consideration the inclusion of this malignancy as part of the syndrome.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • Genetic Alliance. consumer health - Lynch syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846840.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


72. Kotru M, Chandra H, Singh N, Bhatia A: Localized amyloidosis in endometrioid carcinoma of the uterus: a rare association. Arch Gynecol Obstet; 2007 Oct;276(4):383-4
MedlinePlus Health Information. consumer health - Uterine Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized amyloidosis in endometrioid carcinoma of the uterus: a rare association.
  • Amyloidosis of the endometrium is rare and has only been reported as part of a systemic disease.
  • Ultrasonography revealed a growth in the uterine cavity and enlarged internal and external iliac lymph nodes.
  • The histologic diagnosis was that of a well-differentiated endometrioid adenocarcinoma: villoglandular type.
  • CONCLUSION: This is an unusual case of amyloidosis associated with endometrioid carcinoma of the uterus.
  • [MeSH-major] Amyloidosis / complications. Carcinoma, Endometrioid / complications. Endometrial Neoplasms / complications. Uterine Diseases / complications

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17406875.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


73. Kawate S, Takeyoshi I, Ikota H, Numaga Y, Sunose Y, Morishita Y: Endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon. Jpn J Clin Oncol; 2005 Mar;35(3):154-7
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon.
  • This report presents a case of endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon following total abdominal hysterectomy and bilateral salpingo-oophorectomy for leiomyoma of the uterus and infiltrating pelvic endometriosis, and hormone replacement therapy.
  • Based on the diagnosis of mesocolonic tumor, sigmoidectomy with lymph node resection was performed.
  • The tumor cells were immunopositive for cytokeratin 7, but negative for cytokeratin 20, and the tumor was histologically diagnosed as endometrioid adenocarcinoma of the mesocolon.
  • Hyperestrogenism has been implicated as a risk factor for the development of cancer from endometriosis.
  • [MeSH-major] Carcinoma, Endometrioid / etiology. Endometriosis / pathology. Sigmoid Diseases / pathology. Sigmoid Neoplasms / etiology
  • [MeSH-minor] Cell Transformation, Neoplastic / pathology. Colon, Sigmoid / blood supply. Estrogen Replacement Therapy / adverse effects. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Leiomyoma / surgery. Lymph Node Excision. Mesentery / pathology. Middle Aged. Ovariectomy. Postoperative Period. Uterine Neoplasms / surgery

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741306.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


74. Mittal K, Da Costa D: Endometrial hyperplasia and carcinoma in endometrial polyps: clinicopathologic and follow-up findings. Int J Gynecol Pathol; 2008 Jan;27(1):45-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial hyperplasia and carcinoma in endometrial polyps: clinicopathologic and follow-up findings.
  • 1) to evaluate findings in follow-up hysterectomy specimens after a diagnosis of complex atypical hyperplasia or carcinoma in endometrial polyps (EMPs) for possible significance in management strategies; and 2)to identify features in these polyps, that are predictive of the presence of endometrial hyperplasia or carcinoma in subsequent hysterectomy.
  • Records of all cases of EMPs with endometrial hyperplasia were retrieved from the files of New York University Medical Center from 1993 to 2005.
  • Of the 29 patients with complex atypical hyperplasia within the polyp, 19 out of 29 (66%) patients had hyperplasia of the non-polyp endometrium, and adenocarcinoma was observed in 9 out of 29 (31%) patients on follow-up hysterectomy.
  • The percentage of polyp area involved by the hyperplasia was predictive of finding endometrial disorder in subsequent hysterectomy (P = 0.005).
  • Of the 8 patients with adenocarcinoma in situ (AIS) within the polyp 3 (38%) had myoinvasive adenocarcinoma.
  • In contrast, in cases without AIS, 4 out of 21 (19%) had myoinvasive adenocarcinoma in follow-up hysterectomy.
  • Eight of the nine cases with carcinoma in endometrial polyp had endometrial pathology on hysterectomy.
  • Approximately two thirds of the patients with hyperplasia and 90% of patients with adenocarcinoma in endometrial polyps show endometrial pathology on subsequent hysterectomy.
  • The above findings reinforce the need for hysterectomy especially in postmenopausal women with atypical complex hyperplasia or carcinoma in endometrial polyps even if these changes appear confined to the polyp in initial sampling.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Polyps / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156974.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Cabrera S, Franco-Camps S, García A, Vergés R, Díaz-Feijoo B, Pérez-Benavente MA, Poza JL, Bradbury M, Xercavins J, Gil-Moreno A: Total laparoscopic radical hysterectomy for cervical cancer in prolapsed uterus. Arch Gynecol Obstet; 2010 Jul;282(1):63-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total laparoscopic radical hysterectomy for cervical cancer in prolapsed uterus.
  • PURPOSE: The association between cervical cancer and uterine prolapse is rare and sparsely represented in literature, despite the high incidence of the latter.
  • METHODS: We report a case of cervical cancer in prolapsed uterus treated with radical hysterectomy performed totally by laparoscopic approach, and review other case reports published about this clinical condition.
  • RESULTS: We present the first case reported in literature in our knowledge of cervical cancer in prolapsed uterus treated with radical hysterectomy performed totally by laparoscopic approach.
  • CONCLUSIONS: Radical hysterectomy can be correctly performed totally by laparoscopic approach even when cervical cancer is associated with severe uterine prolapse.
  • [MeSH-major] Adenocarcinoma / surgery. Hysterectomy / methods. Uterine Cervical Neoplasms / surgery. Uterine Prolapse / surgery


76. Fleischmann A, Waser B, Gebbers JO, Reubi JC: Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments. J Clin Endocrinol Metab; 2005 Aug;90(8):4722-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments.
  • CONTEXT: Bombesin-like neuropeptides including gastrin-releasing peptide (GRP) and their corresponding receptors, mediate multiple physiological actions and have biological significance in cancer.
  • However, information about the function of these neuropeptides and the incidence, distribution, density, and subtype of their receptors in human uterine tissues is scarce.
  • OBJECTIVE: The objective of the study was to investigate normal and neoplastic human uterine tissues for their bombesin receptor status.
  • PATIENTS: The following tissue samples were taken immediately after surgery: myometrium (n = 41), endometrium (n = 29), leiomyomas (n = 26), leiomyosarcomas (n = 6), endometrial adenocarcinomas (n = 28), and carcinosarcoma (n = 1).
  • RESULTS: Normal uterine tissues expressed GRP receptors (GRP-Rs) in the myometrium, in subsets of secretory endometrial glands, and in subsets of endometrial blood vessels of the late proliferative and the secretory phase.
  • GRP-Rs were also detected in 10 of 28 adenocarcinomas, one of one carcinosarcoma, and in blood vessels surrounding the adenocarcinomas.
  • The expression of GRP-R in glands and vessels during specific phases of the cycle suggests a timely precise physiological action of GRP in these targets; in certain uterine neoplasms, the GRP-R overexpression may contribute to tumor development because GRP is a potent growth factor.
  • The expression of GRP-R in leiomyomas may allow distinguishing them from receptor-negative leiomyosarcomas; GRP-R in leiomyomas, in a subset of endometrial adenocarcinomas, carcinosarcomas, and in peritumoral vessels may be candidates for receptor targeting in vivo.
  • [MeSH-major] Leiomyoma / metabolism. Receptors, Bombesin / metabolism. Uterine Neoplasms / metabolism. Uterus / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Autoradiography. Carcinosarcoma / metabolism. Female. Humans. Leiomyosarcoma / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941862.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Bombesin
  •  go-up   go-down


77. Corrado G, Baiocco E, Carosi M, Vizza E: Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report. Fertil Steril; 2008 Nov;90(5):2006.e5-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report.
  • OBJECTIVE: To describe a case of progression of endometrial complex atypical hyperplasia (CAH) to extrauterine endometrioid adenocarcinoma in a patient who had requested fertility-sparing management.
  • SETTING: Division of Gynecologic Oncology, National Cancer Institute "Regina Elena," Rome, Italy.
  • PATIENT(S): A nulliparous 36-year-old woman with endometrial CAH who decided on a conservative approach.
  • INTERVENTION(S): Conservative hysteroscopic resection of the lesion, the surrounding endometrium, and underlying myometrium plus hormone therapy regimen of megestrol acetate (160 mg) daily for 6 months.
  • RESULT(S): Eighteen months after fertility-sparing management, a laparoscopic operation revealed grade 2 endometrium adenocarcinoma with superficial myometrial invasion and a microscopic metastasis of the left ovary and Douglas peritoneum.
  • CONCLUSION(S): Conservative therapy is feasible in carefully selected young women with endometrial CAH.
  • However, close follow-up is required because of possible progression to endometrial cancer.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / therapy. Endometrial Neoplasms / pathology. Hysteroscopy. Megestrol Acetate / therapeutic use. Precancerous Conditions / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692828.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


78. Scopa CD, Aletra C, Lifschitz-Mercer B, Czernobilsky B: Metastases of breast carcinoma to the uterus. Report of two cases, one harboring a primary endometrioid carcinoma, with review of the literature. Gynecol Oncol; 2005 Feb;96(2):543-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastases of breast carcinoma to the uterus. Report of two cases, one harboring a primary endometrioid carcinoma, with review of the literature.
  • BACKGROUND: Metastases to the uterus are rare, accounting for less than 10% of all cases of metastases to the female genital tract from extragenital cancers.
  • The endometrium is even less frequently affected by metastases.
  • Lobular carcinoma is the most common type of breast cancer that metastasizes to the uterus.
  • CASES: Two cases of infiltrating lobular carcinoma of the breast metastatic to endometrium and myometrium, one of them harboring an endometrioid adenocarcinoma, are reported.
  • Both patients were on tamoxifen therapy and presented with uterine bleeding.
  • CONCLUSION: To the best of our knowledge, uterine carcinoma serving as recipient of metastatic carcinoma from the breast has not been previously documented.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Endometrioid / secondary. Carcinoma, Lobular / secondary. Uterine Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661249.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


79. Krusche CA, Vloet AJ, Classen-Linke I, von Rango U, Beier HM, Alfer J: Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum Reprod; 2007 Nov;22(11):2956-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas.
  • Recently, HDAC inhibitors were shown to enhance differentiation of endometrial fibroblasts and endometrial adenocarcinomas.
  • However, there is only rare information on HDAC and HAT expression in the human endometrium.
  • In endometrial adenocarcinomas (n = 17), HDAC-1 expression was studied by immunohistochemistry.
  • RESULTS: In the human endometrium, HDAC-1, -2, -3 and PCAF mRNA are expressed without cyclical changes.
  • By immunohistochemistry, nuclear expression of HDAC proteins was detected in all endometrial cell types.
  • In the case of HDAC-3, immunostaining was significantly reduced in the endometrial surface epithelium on day 6-10 (P < 0.01 versus days 15-18 and 24-28).
  • Compared to normal endometrium, a high proportion of endometrial adenocarcinomas showed impaired HDAC-1 protein expression in the epithelial and stromal compartment.
  • CONCLUSIONS: Class I HDACs and HATs are expressed in the human endometrium throughout the menstrual cycle, suggesting the cyclic endometrium as a potential target for HDAC inhibitors.
  • We hypothesis that alterations of HDAC and/or HAT expression are potentially involved in impaired endometrial differentiation.
  • [MeSH-major] Adenocarcinoma / enzymology. Endometrial Neoplasms / enzymology. Endometrium / enzymology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adult. Female. Histone Deacetylase 1. Histone Deacetylase 2. Histone Deacetylases / biosynthesis. Humans. Immunohistochemistry / methods. Middle Aged. Repressor Proteins / biosynthesis. Uterus / enzymology. p300-CBP Transcription Factors / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728353.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Repressor Proteins; EC 2.3.1.48 / p300-CBP Transcription Factors; EC 2.3.1.48 / p300-CBP-associated factor; EC 3.5.1.98 / HDAC1 protein, human; EC 3.5.1.98 / Histone Deacetylase 1; EC 3.5.1.98 / Histone Deacetylase 2; EC 3.5.1.98 / Histone Deacetylases; EC 3.5.1.98 / histone deacetylase 3
  •  go-up   go-down


80. Keese M, Back W, Dinter D, Gladisch R, Joos A, Palma P: Case report: late perianal mucinous adenocarcinoma after Crohn's disease proctectomy: an oncological rarity. World J Surg Oncol; 2005 Jun 29;3:42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: late perianal mucinous adenocarcinoma after Crohn's disease proctectomy: an oncological rarity.
  • BACKGROUND: As in ulcerative colitis, there is an increased incidence of colorectal carcinoma in Crohn's disease.
  • While carcinoma formation originating from ano-rectal fistulas is generally considered as a rare event there are different publications reporting on mucinous adenocarcinoma formation in association with a neovagina and rectovaginal fistulas.
  • To the best of our knowledge this is the first description of a perianal mucinous adenocarcinoma arising in a patient after Crohn's disease proctocolectomy.
  • CASE PRESENTATION: We report the case of a 50-year old female with a mucinous adenocarcinoma forming in the perineum eleven years after proctocolectomy for Crohn's disease.
  • The patient was readmitted with perineal pain, leucocytosis and a perineal mass highly suspicious of abscess formation in the MRI-Scan.
  • Histological examination revealed a mucinous adenocarcinoma.
  • Exenteration including vagina, uterus and ovaries together with the coccygeal-bone was performed.
  • CONCLUSION: Mucinous adenocarcinoma formation is a rare complication of Crohn's disease and so far unreported after proctocolectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):443-50 [9106694.001]
  • [Cites] J Surg Oncol. 2001 May;77(1):61-4 [11344485.001]
  • [Cites] Eur J Surg. 2000 Mar;166(3):218-22 [10755336.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):272-5 [8314151.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(2):CD000279 [15106148.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):266-8 [15047250.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:6-9 [12950414.001]
  • [Cites] Colorectal Dis. 2003 Sep;5(5):490-5 [12925087.001]
  • [Cites] Z Gastroenterol. 2002 Aug;40(8):569-76 [12297980.001]
  • [Cites] Am J Surg. 1980 Nov;140(5):642-4 [7435823.001]
  • [Cites] Am Surg. 1988 Nov;54(11):681-5 [2847606.001]
  • [Cites] Cancer. 1977 Mar;39(3):1295-9 [199346.001]
  • [Cites] Ann Surg. 1938 Nov;108(5):867-73 [17857277.001]
  • [Cites] Dis Colon Rectum. 1975 Apr;18(3):200-2 [1140047.001]
  • (PMID = 15987512.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1190221
  •  go-up   go-down


81. Sameshima H, Nagai K, Ikenoue T: Single vaginal ectopic ureter of fetal metanephric duct origin, ipsilateral kidney agenesis, and ipsilateral rudimentary uterine horn of the bicornuate uterus. Gynecol Oncol; 2005 Apr;97(1):276-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single vaginal ectopic ureter of fetal metanephric duct origin, ipsilateral kidney agenesis, and ipsilateral rudimentary uterine horn of the bicornuate uterus.
  • CASE: Two Japanese women had a single ectopic ureter opening in the central wall of the vagina, ipsilateral kidney agenesis, and ipsilateral rudimentary uterine horn of the bicornuate uterus.
  • One had squamous cell carcinoma of the uterine cervix, and the other had adenocarcinoma of the vagina arising from the ectopic ureter meatus, which was histologically confirmed as fetal metanephric duct remnant.
  • Clinically, the ectopic vaginal ureter is important as a possible background of vaginal adenocarcinoma, and information on the ureter-like duct course is required during surgery.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Kidney / abnormalities. Ureter / abnormalities. Uterine Cervical Neoplasms / etiology. Uterus / abnormalities. Vaginal Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790476.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Han CP, Kok LF, Wang PH, Wu TS, Tyan YS, Cheng YW, Lee MY, Yang SF: Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. Mod Pathol; 2009 Jun;22(6):797-806
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study.
  • Endocervical adenocarcinomas and endometrial adenocarcinomas are malignancies that affect uterus; however, their biological behaviors are quite different.
  • The purpose of this study is to evaluate four different scoring methods of p16(INK4a) immunohistochemical staining in distinguishing between primary endocervical adenocarcinomas and endometrial adenocarcinomas from limited sizes of tissue specimens.
  • A tissue microarray was constructed using formalin-fixed, paraffin-embedded tissue from hysterectomy specimens, including 14 endocervical adenocarcinomas and 21 endometrial adenocarcinomas.
  • Of the four scoring methods for p16(INK4a) expression, Method Nucleus, Method Dominant Cytoplasm or Nucleus, and Method Mean of Cytoplasm plus Nucleus showed significant (P values <0.05), but Method Cytoplasm did not show significant (P=0.432), frequency distinction between endocervical adenocarcinomas and endometrial adenocarcinomas.
  • According to the data in this tissue microarray study, Method Nucleus is the most convenient and efficient method to distinguish between endocervical adenocarcinomas and endometrial adenocarcinomas.
  • Method Cytoplasm is of no use in the diagnostic distinction between endocervical adenocarcinomas and endometrial adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Endometrial Neoplasms / diagnosis. Tissue Array Analysis. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347018.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


83. Faruqi SA, Harsch C, Saquib M, Noumoff J: Clonal Variation within an Adenocarcinoma of the Endometrium Cultured in Different Substrates and Media. J Assoc Genet Technol; 2009;35(1):5-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal Variation within an Adenocarcinoma of the Endometrium Cultured in Different Substrates and Media.
  • An adenocarcinoma of the endometrium was cultured separately in four different combinations of two substrates (normal tissue culture plastic and PrimariaTM) and two media (RPMI-1640 and serum free LHC-9).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252255.001).
  • [ISSN] 1523-7834
  • [Journal-full-title] Journal of the Association of Genetic Technologists
  • [ISO-abbreviation] J Assoc Genet Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Hirabayashi K, Yasuda M, Kajiwara H, Nakamura N, Sato S, Nishijima Y, Mikami M, Osamura RY: Clear cell adenocarcinoma arising from adenomyosis. Int J Gynecol Pathol; 2009 May;28(3):262-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma arising from adenomyosis.
  • An elevated level of CA125 in the blood favored a diagnosis of malignant uterine body tumor, but was not confirmed by endometrial cytology and biopsy.
  • Resection of the uterus revealed a solid whitish tumor in the myometrium that was diagnosed as clear cell adenocarcinoma (CCA) arising from adenomyosis.
  • There were transitions between endometrial epithelium of adenomyosis, noninvasive CCA, and invasive CCA.
  • Immunohistochemical expression of hepatocyte nuclear factor-1beta supported the diagnosis of CCA.
  • Malignant tumor arising from adenomyosis should be considered as a differential diagnosis when the serum level of tumor markers such as CA125 is high and when the tumor is intramyometrial.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. CA-125 Antigen / blood. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620944.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


85. Kalogiannidis I, Lambrechts S, Amant F, Neven P, VAN Limbergen E, Vergote I: Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: An analysis of 208 patients. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1885-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: An analysis of 208 patients.
  • Two hundred and eight patients with a clinical stage I endometrial carcinoma were studied (164 fulfilled the inclusion criteria).
  • High risk was defined as nonendometrioid, or endometrioid tumors grade 3 (G3), or G2 with any or G1 with deep (>1/2) myometrial infiltration.
  • Patients with low-risk (group A, n = 85) and high-risk disease confined to the uterus (group B, n = 57) did not receive adjuvant radiotherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Lymph Node Excision / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009987.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Hatami M, Del Priore G, Chudnoff SG, Goldberg GL: Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy. Arch Iran Med; 2006 Oct;9(4):413-6
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy.
  • A 32-year-old female was diagnosed by loop electrosurgical excision procedure with adenocarcinoma in situ and a focus suspicious for positive lympho-vascular invasion.
  • An abdominal radical trachelectomy was performed to preserve her uterus and fertility.
  • We concluded that abdominal radical trachelectomy may be a surgical option for early stage cervical cancer treatment in young women who wish to preserve fertility.
  • [MeSH-major] Adenocarcinoma / surgery. Gynecologic Surgical Procedures / methods. Lymph Node Excision / methods. Uterine Cervical Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061618.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


87. Yang YP, Zhu YL, Wu WP, Wang ZM, Zhang JM: [Perivascular epithelioid cell tumor of uterus: report of 5 cases and literature review]. Zhonghua Bing Li Xue Za Zhi; 2007 May;36(5):302-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Perivascular epithelioid cell tumor of uterus: report of 5 cases and literature review].
  • OBJECTIVE: To study the pathologic features, diagnosis, differential diagnosis and biologic behavior of uterine perivascular epithelioid tumor.
  • METHODS: Five cases of uterine perivascular epithelioid cell tumor were studied by light microscopy and immunohistochemistry.
  • CONCLUSIONS: Perivascular epithelioid cell tumor is a rare mesenchymal tumor of uterus, with distinctive histologic and immunohistochemical features.
  • It should be distinguished from clear cell carcinoma and epithelioid leiomyoma of uterus.
  • Positivity for melanocytic markers (especially HMB45) plays an important role in the diagnosis of this tumor.
  • In general, the tumor is categorized as benign, with uncertain malignant potential and malignant.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Neoplasm Proteins / metabolism. Perivascular Epithelioid Cell Neoplasms / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adult. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Leiomyoma, Epithelioid / pathology. Melanoma-Specific Antigens. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706136.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Desmin; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  • [Number-of-references] 24
  •  go-up   go-down


88. Gonçalves R, Linhares E, Albagli R, Valadão M, Vilhena B, Romano S, Ferreira CG: Occurrence of other tumors in patients with GIST. Surg Oncol; 2010 Dec;19(4):e140-3
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Evaluate the presence of other tumors in cohort of patients with GIST treated at a cancer treatment referral center - INCA.
  • Immunohistological diagnosis was confirmed by a pathologist specialized in sarcomas.
  • The mean size of lesions was 4.79 cm (0.3-15 cm), with malignant potential low/very low in 7 cases (50%), intermediate in 5 cases (35.7%) and high in 2 cases (14.3%).
  • The diagnosis of GIST was incidental in 6 cases and in one case the non-GIST tumor was incidental.
  • The non-GIST tumors were most frequent in the stomach (adenocarcinoma), in 4 cases (28.5%) and colon/rectum (adenocarcinoma) in 4 other cases.
  • The other sites involved were breast (ductal carcinoma), kidney (clear cell carcinoma), prostate (adenocarcinoma), endometrium (adenocarcinoma), ovary (adenocarcinoma) and adrenal (neuroblastoma), with one case each.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Brazil / epidemiology. Child. Colonic Neoplasms / epidemiology. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Rectal Neoplasms / epidemiology. Retrospective Studies. Stomach Neoplasms / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20675121.001).
  • [ISSN] 1879-3320
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


89. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J: Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer; 2006 Feb 15;106(4):812-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.
  • BACKGROUND: Adenocarcinoma of the endometrium is the most common gynecologic malignancy in the United States, accounting for approximately 36,000 diagnoses of invasive carcinoma annually.
  • The most common histologic type, endometrioid adenocarcinoma (EC), accounts for 75-80% of patients.
  • The objective of this work was to estimate the prevalence of concurrent carcinoma in women with a biopsy diagnosis of the precursor lesion, atypical endometrial hyperplasia (AEH).
  • METHODS: This prospective cohort study included women who had a community diagnosis of AEH.
  • Of these, 17 women were not included in the analysis: Two patients had unreadable slides because of poor processing or insufficient tissue, 2 patients had only slides that were not endometrial, the slides for 5 patients were not available for review, and 8 of the hysterectomy specimens were excluded because they showed evidence of interval intervention, either progestin effect or ablation.
  • The study panel review of the AEH biopsy specimens was interpreted as follows: 74 of 289 specimens (25.6%) were diagnosed as less than AEH, 115 of 289 specimens (39.8%) were diagnosed as AEH, and 84 of 289 specimens (29.1%) were diagnosed as endometrial carcinoma.
  • In 5.5% (16 of 289 specimens), there was no consensus on the biopsy diagnosis.
  • The rate of concurrent endometrial carcinoma for analyzed specimens was 42.6% (123 of 289 specimens).
  • Among the women who had hysterectomy specimens with carcinoma, 14 of 74 women (18.9%) had a study panel biopsy consensus diagnosis of less than AEH, 45 of 115 women (39.1%) had a study panel biopsy consensus diagnosis of AEH, and 54 of 84 women (64.3%) had a study panel diagnosis of carcinoma.
  • Among women who had no consensus in their biopsy diagnosis, 10 of 16 women (62.5%) had carcinoma in their hysterectomy specimens.
  • CONCLUSIONS: The prevalence of endometrial carcinoma in patients who had a community hospital biopsy diagnosis of AEH was high (42.6%).
  • When considering management strategies for women who have a biopsy diagnosis of AEH, clinicians and patients should take into account the considerable rate of concurrent carcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Endometrial Hyperplasia / complications. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • [CommentIn] Cancer. 2006 Feb 15;106(4):729-31 [16400641.001]
  • (PMID = 16400639.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


90. Niwa T, Yoshida T, Doiuchi T, Ito K, Nakayama H, Odagiri K, Inoue T: Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy. Br J Radiol; 2008 Aug;81(968):659-65
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy.
  • We retrospectively assessed the factors that may impede tumour reduction of locally advanced cervical adenocarcinoma treated with balloon-occluded arterial infusion chemotherapy (BOAI) as initial therapy.
  • BOAI was performed via uterine arteries in 21 patients, and via the anterior division or main trunk of the internal iliac artery (when the uterine arteries were obscured) in 10 patients.
  • Internal iliac arterial infusion significantly correlated with "no response" compared with uterine arterial infusion (p<0.001).
  • These data suggest that uterine arteries being obscured to arterial infusion may be associated with a poor response to BOAI for cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Catheterization / methods. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Female. Humans. Infusions, Intra-Arterial / methods. Magnetic Resonance Imaging. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Risk Factors. Uterus / blood supply

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628334.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


91. Wani Y, Notohara K, Tsukayama C: Mesonephric adenocarcinoma of the uterine corpus: a case report and review of the literature. Int J Gynecol Pathol; 2008 Jul;27(3):346-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesonephric adenocarcinoma of the uterine corpus: a case report and review of the literature.
  • Mesonephric adenocarcinoma (MA) is a rare tumor of the female genital tract, mainly in the cervix and vagina, which is usually associated with mesonephric remnants or mesonephric hyperplasia.
  • In the uterus corpus, MA is as rare as mesonephric structures, and only a few cases have been previously reported.
  • Here, we report a rare case of MA of the uterine corpus.
  • Abdominal computed tomography scan confirmed a uterine tumor measuring 8.6 cm.
  • In addition, the ductal pattern simulating endometrioid adenocarcinoma was also noted.
  • Other elements consisted of a retiform pattern, serous adenocarcinoma-like papillary budding, and glomeruloid morphology.
  • We review the previously published cases of MA and discuss the principal differential diagnosis of MA in the uterine corpus.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580312.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


92. Mylonas I, Makovitzky J, Shabani N, Richter DU, Kuhn C, Jeschke U, Briese V, Friese K: Leukaemia inhibitory factor (LIF) is immunohistochemically expressed in normal, hyperplastic and malignant endometrial tissue. Eur J Obstet Gynecol Reprod Biol; 2005 Jan 10;118(1):101-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukaemia inhibitory factor (LIF) is immunohistochemically expressed in normal, hyperplastic and malignant endometrial tissue.
  • Therefore, the aim of this study was to determine the frequency and tissue distribution of LIF in normal, hyperplastic and malignant endometrium.
  • STUDY DESIGN: Paraffin-fixed endometrial tissue was obtained from normal premenopausal women (n = 15), endometrial hyperplasia (n = 20), endometroid adenocarcinoma (n = 32) and endometrial polyps (n = 9).
  • RESULTS: The lowest expression of LIF was observed in endometrial adenocarcinomas compared to all groups, while endometrial polyps expressed the highest LIF immunostaining.
  • The highest expression of LIF was observed in endometrial polyps.
  • Simple hyperplasia showed a significantly higher LIF expression than proliferative endometrium and adenocarcinoma.
  • Adenomatous hyperplasia (AH) grade I-III had a significantly higher LIF expression than adenocarcinoma.
  • The lowest expression of LIF was observed in adenocarcinoma, being statistically significant compared to all groups.
  • CONCLUSION: LIF was immunohistochemically demonstrated in normal, hyperplastic and malignant endometrial tissue, suggesting a widespread but complex role for LIF in hyperplastic and malignant endometrial growth regulation.
  • AH I-III also expressed LIF with statistically higher immunostaining than adenocarcinoma.
  • Since AH III can be considered as a precursor of endometrial cancer, LIF could be a marker of cell transformation.
  • [MeSH-major] Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / chemistry. Endometrium / chemistry. Immunohistochemistry. Interleukin-6 / analysis
  • [MeSH-minor] Adenocarcinoma / chemistry. Female. Humans. Leukemia Inhibitory Factor. Polyps / chemistry. Premenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15596282.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / LIF protein, human; 0 / Leukemia Inhibitory Factor
  •  go-up   go-down


93. Patai K, Dévényi L, Hubay M, Csömör S, Zelkó R: Phosphor/sulphur ratio: an indicator of malignant uterus change. Oncol Res; 2005;15(4):215-7
Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphor/sulphur ratio: an indicator of malignant uterus change.
  • The purpose of the present study was to establish a correlation between gynaecological diseases (myoma, adenocarcinoma) and phosphor/sulphur (P/S) ratios of different regions of the uterus.
  • The results of the nonparametric statistical test (Wilcoxon rank-sum test) indicate that the P/S ratios were significantly higher in adenocarcinoma (0.8891 +/- 0.0757) than in myoma (0.4713 +/- 0.0306).
  • [MeSH-major] Adenocarcinoma / pathology. Leiomyoma / pathology. Phosphorus / analysis. Sulfur / analysis. Uterine Neoplasms / pathology. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. Sulfur, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822281.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphatidylcholines; 27YLU75U4W / Phosphorus; 70FD1KFU70 / Sulfur
  •  go-up   go-down


94. Wallace AE, Gibson DA, Saunders PT, Jabbour HN: Inflammatory events in endometrial adenocarcinoma. J Endocrinol; 2010 Aug;206(2):141-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory events in endometrial adenocarcinoma.
  • Endometrial adenocarcinoma is the most common gynaecological malignancy in western countries.
  • Many of the established risk factors for developing endometrial cancer are associated with excess exposure to oestrogen unopposed by progesterone.
  • However, a number of risk factors also promote inflammation, another feature proposed to influence cancer development.
  • The human cycling endometrium undergoes regular and cyclical episodes of inflammation.
  • Moreover, hormonal and genetic changes that occur early in the development of endometrial adenocarcinoma can exacerbate the local inflammatory environment.
  • Via alterations in the expression of local mediators and immune cell function, these may contribute to the development of endometrial cancer.
  • This review discusses the contribution of inflammation to the initiation and progression of endometrial adenocarcinoma.
  • Manipulation of inflammatory pathways may therefore represent a therapeutic target in endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Inflammation

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406782.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127685844; United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01; United Kingdom / Medical Research Council / / U.1276.00.002.00005.01 (85844); United Kingdom / Medical Research Council / / U1276.00.002.00005.01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 0 / Chemokines; 0 / Cytokines; 0 / Estrogens; 0 / Glucocorticoids; 0 / KRAS protein, human; 0 / NF-kappa B; 0 / Prostaglandins; 0 / Proto-Oncogene Proteins; 4G7DS2Q64Y / Progesterone; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 190
  •  go-up   go-down


95. Shaco-Levy R, Piura B: Endometrioid endometrial adenocarcinoma recurring as carcinosarcoma. J Obstet Gynaecol Res; 2008 Apr;34(2):279-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid endometrial adenocarcinoma recurring as carcinosarcoma.
  • Müllerian carcinosarcoma is currently regarded as a metaplastic (sarcomatous) carcinoma.
  • Only five cases of pure ovarian adenocarcinoma recurring as carcinosarcoma have been documented in the literature.
  • There are no documented cases of endometrial adenocarcinoma recurring as metaplastic carcinoma.
  • We report of a case of endometrial adenocarcinoma, endometrioid type, recurring as metaplastic carcinoma showing sarcomatous differentiation.
  • The tumor evolution in this case supports the prevailing opinion that Müllerian carcinosarcomas are derived from carcinomas and represent tumor progression.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinosarcoma / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18412798.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


96. Xiaoxin M, Yingnan J, Yanxia L, Shu L, Yuanqi H, Hongwei L: Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth. Int J Gynecol Cancer; 2009 Oct;19(7):1182-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth.
  • OBJECTIVE: : To investigate the effect of aspirin on human Ishikawa adenocarcinoma endometrium cell proliferation and apoptosis and its related mechanism through in vitro experiments.
  • METHODS: : The effects on Ishikawa adenocarcinoma endometrium cell proliferation and cell cycle of aspirin at different intervals and concentrations were determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method and flow cytometry; cell morphous change after the effect of aspirin was observed with transmission electron microscope; and the effect of aspirin on B-cell lymphoma/leukemia-x, long (Bcl-xl) proteinum expression was determined with Western blot.
  • RESULTS: : Aspirin had a significant depressant effect on human Ishikawa adenocarcinoma endometrium cell proliferation, and the effect showed time and dose dependence (P < 0.05).
  • CONCLUSIONS: : Aspirin has a distinct depressant effect on human Ishikawa adenocarcinoma endometrium cell growth, and its effect may be realized by lowering Bcl-xl proteinum expression.
  • [MeSH-major] Adenocarcinoma / pathology. Aspirin / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Endometrial Neoplasms / pathology

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820387.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / bcl-X Protein; R16CO5Y76E / Aspirin
  •  go-up   go-down


97. Nishiyama S, Okudaira M, Saito N: Mechanisms of rolipram-induced increase in the incidence of mammary adenocarcinoma: histopathological study of a 104-week oral carcinogenicity study in female Sprague-Dawley rats. Arch Toxicol; 2006 Feb;80(2):88-97
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of rolipram-induced increase in the incidence of mammary adenocarcinoma: histopathological study of a 104-week oral carcinogenicity study in female Sprague-Dawley rats.
  • The present study was carried out to elucidate the mechanisms behind an increase in the incidence of malignant or multiple mammary tumors as a result of oral administration of rolipram in a 104-week carcinogenicity study.
  • No treatment-related effects were seen in males; however, in females, there was a significant increase in the number of malignant or multiple mammary tumor bearers at a dose of 2.0 mg/kg.
  • To clarify the mechanisms behind a rolipram-induced increase in the incidence of mammary adenocarcinoma at time points earlier than 104 weeks, the hormonal changes associated with pituitary adenoma were identified, and estrous cycling in the ovary, uterus, and vagina were examined in female rats treated with rolipram for 52 weeks.
  • There was also a dose-dependent relationship with PRL-producing pituitary adenomas.
  • Changes in estrous cycling in the uterus and vagina and a decrease in the size and number of corpora lutea in the ovaries of female rats treated with rolipram at 2.0 mg/kg for 52 weeks indicated that an increase in the estrus phase of the cycle corresponded to a marked decrease in the diestrus phase, which might result from the increased plasma estrogen concentration.
  • Together, all of the above mentioned data suggest that rolipram not only stimulates an increase in the number and size of PRL adenomas in the pituitary gland but also in the estrus phase of the estrous cycle.
  • These events might cause progression of the mammary gland tissues from hyperplasia to carcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Mammary Neoplasms, Experimental / chemically induced. Phosphodiesterase Inhibitors / toxicity. Pituitary Neoplasms / chemically induced. Prolactinoma / chemically induced. Rolipram / toxicity

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167140.001).
  • [ISSN] 0340-5761
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Phosphodiesterase Inhibitors; 4TI98Z838E / Estradiol; 9002-62-4 / Prolactin; K676NL63N7 / Rolipram
  •  go-up   go-down


98. Maeda D, Takazawa Y, Ota S, Takeuchi Y, Seta A, Nakagawa S, Yano T, Taketani Y, Fukayama M: Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear. Int J Gynecol Pathol; 2010 May;29(3):273-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear.
  • Primary adenocarcinoma of the fallopian tube is an uncommon female genital tract tumor.
  • In situ or minimally invasive tubal cancer often poses a diagnostic challenge because of the absence of specific clinical and radiological findings.
  • Here, we report a rare case of bilateral microscopic fallopian tube cancer that initially presented with malignant findings in an endometrial cytologic smear.
  • An endometrial smear performed during a routine checkup revealed clusters of malignant cells.
  • During the clinical diagnosis of endometrial cancer, she underwent bilateral salpingo-oophorectomy, total hysterectomy, and partial omentectomy.
  • Histologically, no carcinoma was found in the uterus or ovaries.
  • In toto sectioning of the fallopian tubes and their fimbriated ends revealed minute foci of serous adenocarcinoma in the left tubal mucosa and right fimbria.
  • In situ adenocarcinoma components were present in both lesions.
  • Microinvasive carcinoma was observed in the right fimbria.
  • Although there was no macroscopic dissemination in the peritoneum at the time of surgery, positive intraoperative peritoneal cytology suggests that the patient was at risk of developing peritoneal serous carcinoma if not treated.
  • Clinicians and pathologists should consider the possibility of early tubal cancer when there is no clinically detectable pelvic mass, and malignant cells appear in endometrial cytology specimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407329.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Kato H, Kanematsu M, Furui T, Imai A, Hirose Y, Kondo H, Goshima S, Tsuge Y: Carcinosarcoma of the uterus: radiologic-pathologic correlations with magnetic resonance imaging including diffusion-weighted imaging. Magn Reson Imaging; 2008 Dec;26(10):1446-50
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma of the uterus: radiologic-pathologic correlations with magnetic resonance imaging including diffusion-weighted imaging.
  • The authors describe the MRI findings, including diffusion-weighted imaging findings, of histopathologically proven uterine carcinosarcoma in four postmenopausal women.
  • In the remaining patient, diffusion-weighted and ADC mapping images clearly distinguished components of adenocarcinoma from sarcoma.
  • Diffusion-weighted images were found to demonstrate complicated tissue components in carcinosarcomas of the uterus, and thus, which may be useful for the diagnosis of this disease.
  • [MeSH-major] Carcinosarcoma / pathology. Magnetic Resonance Imaging / methods. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501546.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


100. Kok LF, Lee MY, Tyan YS, Wu TS, Cheng YW, Kung MF, Wang PH, Han CP: Comparing the scoring mechanisms of p16INK4a immunohistochemistry based on independent nucleic stains and independent cytoplasmic stains in distinguishing between endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet; 2010 Feb;281(2):293-300
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparing the scoring mechanisms of p16INK4a immunohistochemistry based on independent nucleic stains and independent cytoplasmic stains in distinguishing between endocervical and endometrial adenocarcinomas in a tissue microarray study.
  • BACKGROUND: Endocervical adenocarcinomas (ECAs) and endometrial adenocarcinomas (EMAs) are malignancies that affect the uterus; however, their biological behaviors are quite different.
  • [MeSH-major] Adenocarcinoma / pathology. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Endometrial Neoplasms / pathology. Immunohistochemistry / methods. Uterine Cervical Neoplasms / pathology






Advertisement